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INTRODUCTION
CERVICAL INTRAEPITHELIAL NEOPLASIA
Classification of the cervical intraepithelial neoplasia
The cervical  intraepithelial  neoplasia  (CIN) is  a  pre-cancerous lesion  of  uterine 
cervical squamous cell carcinoma (SCC) and is characterized by potentially premalignant 
transformation  and  abnormal  growth,  named  dysplasia,  of  cervical  keratinocytes.  The 
histological  classification  system provides  three  CIN grades  referred  to  as  CIN1 (mild 
dysplasia),  CIN2 (moderate  dysplasia)  and CIN3 (severe  dysplasia)  lesions.  Each  CIN 
grade  remains  confined  to  the  cervical  epithelium  (Figure  1,  A, 
www.lookfordiagnosis.com)  and has  a  variable  potential  evolution  towards  the  cancer. 
CIN1 lesions are characterized by keratinocytes with abnormal cell growth, perinuclear 
cytoplasmic vacuolation,  named koilocytosis,  and increase volume of the nucleus.  This 
histologic change is confined to the basal third of the cervical epithelium (Figure 1, B). 
CIN2 lesions, compared to CIN1, are characterized by higher cytologic atypia and cellular 
disorganization, while koilocytosis is lower or absent. The histological abnormalities are 
confined to the basal two thirds of the cervical epithelium (Figure 1, C). CIN2 cervical 
cells  show two  main  features:  (i)  atypical  mitotic  figures  induced  by  aneuploidy;  (ii) 
abnormal  nucleus/cytoplasm  ratio.  CIN3  lesions  are  characterized  by  keratinocytes 
endowed  with  high  proliferative  index,  immaturity  and  vertical  orientation.  Abnormal 
keratinocytes exceed the two thirds of the epithelium or expand throughout the thickness of 
the epithelium, altering the whole cyto-architecture of the tissue (Figure 1, D). 
Figure 1. Histological  representation of normal and CIN tissue.  (A) Normal cervical  
epithelium;  (B)  CIN1,  disorganization of  the lower third of  the  epithelium;  (C) CIN2,  
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disorganization  of  the  lower half  of  the epithelium with  viral  infection;  (D) CIN3,  the  
disorganization of the epithelium is evident in more than 2/3 lower. 
Epidemiology of the CIN lesions 
The incidence of CIN lesions in a population depends on several factors such as 
etiopathogenetic factors, the efficiency of prevention programs, the immunologic status, 
and the age of the female. The World Health Organization (WHO) has estimated that the 
annual incidence of CIN lesions among women aged 25-65 years who undergo cervical 
SCC screening for the first time was 3-10% for CIN 1 and 1-5% for CIN2 and CIN3. CIN2 
and CIN3 lesions  are  generally  diagnosed in  women  between 25 and 35 years  of  age 
(Kumar et al., 2007). On the contrary, cervical SCC is usually detected in women over 40 
years of age, typically 8 to 13 years after a diagnosis of CIN3. Women can develop CIN 
lesions at any age?. The prevalence of CIN lesions varies from 1/10,000 in women aged 
15-19 years to 1/1,000 in women aged 25-29 and then it reduces to 8/10,000 in women 
aged 25-29 years (WHO 2010). In developing Countries, like Nigeria, the mean age for 
CIN lesion is about 37 years. The prevalence is 3.6% for CIN1, 0.8% for CIN2 and 0.4% 
for CIN3. Such a result is due to the lack of screening methods and it mirrors the typical 
trend of developing Nations (Oguntayo and Samaila, 2012).
Clinical progression of CIN lesions 
The  temporal  progression  CIN1>  CIN2>  CIN3  represents  the  initial  steps  in 
tumorigenesis  of cervical  SCC. However,  CIN lesions do not always  progress towards 
cancer. Indeed, the histological and molecular phenotype of CIN reflects a fine balance 
between  the  factors  that  promote/accelerate  or  reduce/slow  down  disease  progression 
(Melsheimer et al, 2001). About 90% low-grade CIN lesions tend to regress spontaneously 
while 10% women progress to high grade CIN2 and CIN3 lesions. Typically, the risk of 
CIN progression to cancer is related to the severity of CIN lesion. Indeed, the probability 
that a CIN3 lesion progresses towards cervical SCC is significantly higher than CIN1. The 
percentage of regression and progression of different grades of CIN lesions are shown in 
Table 1:
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Lesion Regression Persistence Progression to CIN3
Progression to 
SCC
       CIN1 57% 32% 11% 1%
CIN2 43% 35% 22% 1.5%
CIN3 32% <56% - >12%
Table 1. Regression, persistence and progression to CIN3 or SCC probability of different  
CIN pre-cancerous lesions.
CIN lesions are believed to progress over time, evolving from low-grade neoplasia 
(CIN1),  to  high-grade  neoplasia  (CIN2  and  CIN3),  and  finally  to  invasive  carcinoma 
(Ostor, 1993). Accurate predictions of the progression rates of CIN lesions are limited due 
to a lack of sensitive markers  for neoplastic  progression.  Untreated CIN1 lesions have 
about 10% progression rate to CIN3, whereas CIN2 have about 20% progression rate to 
CIN3 and CIN3 lesions have rates of about 12% to progress to cervical SCC (Ostor, 1993; 
Castle et al., 2009; Moscicki  et al.,  2010). Traditionally, CIN1 lesions are conservatively 
managed and followed in time, while CIN2 and CIN3 are surgically removed. Thus, it can 
be speculated that many women, whose CIN would not evolve to malignant lesions, are 
unnecessarily  candidate  to  follow-up or  even  over-treated  and  exposed  to  the  risks  of 
surgical  excision  (Shanbhag  et  al.,  2009).  These  data  suggest  that  there  is  a  need  for 
sensitive markers that can be used in routine pathology practice to identify CIN lesions 
with a high risk of progression.  
HUMAN PAPILLOMA VIRUS 
Human  papillomavirus  (HPV)  is  the  necessary  cause  of  both  CIN  lesions  and 
cervical SCC (Park et al., 1995; Schiffman and Brinton, 1995; Bosch et al., 2002). HPV is 
a  small  double-stranded  (ds)  DNA  virus  belonging  to  Papillomaviridae  family. 
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Papillomaviridae family is divided into 16 genres defined phylogenetically by the letters of 
the greek alphabet (De Villiers  et al., 2004). Five of them, Alpha, Beta, Gamma Mu and 
Nu,  belong  to  the  human  papillomavirus  (Figure  2).  The  α-Papillomavirus  are 
predominantly mucosal, while other genres are predominantly cutaneous. Approximately 
40 HPV types show ano-genital tropism and are transmitted by sexual activity.  Among 
these, some HPV cause genital warts, while others produce persistent infections that may 
evolve in CIN lesions and cervical SCC (Schiffman et al., 2003). For these reasons, HPVs 
are divided into high- and low- oncogenic risk due to their ability to induce benign genital 
warts or CIN lesions and cervical SCC (Table 2). High-risk HPVs are detected in 90% of 
cervical cancers (Clifford et al., 2003; Muñoz et al., 2003). High-risk HPV16 and HPV18 
are detected in approximately in 50% and in 10-20% of all cervical cancers, respectively 
(Muñoz  et  al.,  2003).  Low-risk  HPVs  are  associated  with  90% of  the  warts,  benign 
squamous papillomas and CIN1 lesions, that in most cases resolve spontaneously (Muñoz 
et al., 2003). 
HPV Group HPV type
High Risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82
Low Risk 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108
Probably High-Risk 26, 53, 66, 68, 73, 82
Table 2. Epidemiologic classification of High-, Low- and Probably High-risk HPVs 
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Figure 2. Phylogenetic tree of 118 types of papillomavirus. Each HPV type is identified  
by the number at the end of  each cluster.  The number above the semicircular  symbol  
identifies  the  papillomavirus  species.  The  greek  symbols  identify  genres.  HPV16  and  
HPV18, the main responsible of cervical cancer, are highlighted in red.
Molecular structure of HPV 
HPV  is  a  small  envelope-free  double-stranded  (ds)  DNA  virus.  The  virion  is 
composed by a proteic capsid (diameter=55 nm) consisting of 72 pentameric or hexameric-
shaped  capsomeres  in  icosahedral  symmetry  (Figure  3, 
https://visualsonline.cancer.gov/details.cfm?imageid=2255).  Viral  DNA is  located  inside 
the capsid. HPV genome is circular, double-stranded and it is composed of approximately 
8,000 base pairs (Narisawa-Saito and Kiyono, 2007). The genetic information is contained 
in only one DNA filament (positive strand) whereas 8 are the coding regions are eight. Six 
coding regions are defined “early” and tagged E1, E2, E4, E5, E6 and E7, whereas two are 
called “later” and tagged L1 and L2 (Bravo and Alonso 2007).
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Figure 3. Electron micrograph of a HPV 16. 
HPV  genome  can  be  divided  into  three  regions:  (i)  Long  Control  Region  (LCR),  or 
upstream  regulatory  region  (URR),  which  is  a  non-coding  region  required  for  viral 
replication and viral DNA encapsidation; (ii) Early region (E), that represents 45% of the 
viral DNA and contains the six E genes expressed early in the HPV life cycle; (iii) Late 
Region (L), corresponds to 40% of the viral DNA and encodes for the structural proteins of 
capsid, L1 and L2 (Muñoz et al., 2006). The “E” and “L” regions are referred to as ORF 
(Open Reading Frame) and are separated by the LCR region (Muñoz et al., 2006). 
The viral genes are transcribed in a clockwise direction, but the transcription is not 
temporally sequential.  The encoded proteins have the same nomenclature of genes: six 
nonstructural regulatory proteins, E1, E2, E4, E5, E6 and E7 that interact with the host 
genome  and  proteins  to  replicate  viral  DNA,  and  two  structural  proteins  L1  and  L2, 
expressed after replication of viral DNA. Each viral protein has a specific function in the 
viral replication cycle. E1 and E2 are specifically involved in DNA replication, while E4, 
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E5, E6, and E7 contribute to the initial destabilization of proliferation and differentiation of 
the  host  cell  (Bravo and Alonso,  2007).  E1 plays  a  major  role  in  the  initial  phase  of 
replication  of  the viral  genome as it  presents  the ATP-dependent  helicase  activity  that 
allows  recognition  and  beginning  of  viral  DNA  replication.  E2  gene  encodes  several 
proteins that regulate early viral gene transcription and viral DNA replication, thanks to a 
structural sequence that binds specific DNA regions (Wilson et al., 2002). At low levels, 
E2 binds specific recognition sequences and activates early viral promoters, while at high 
concentrations  it  represses  viral  transcription  by  blocking  the  binding  to  transcription 
factors. E2 plays a key role in the direct regulation of the levels of E6 and E7 oncoproteins. 
Indeed, loss of E2 expression is the first stage of neoplastic transformation.  Despite its 
name, E4 is expressed during the final phases of the viral replication cycle: it seems to 
interact with the keratin intermediate filaments, making them mechanically unstable and 
thus  facilitating  the  release  of  mature  virions  from  the  keratinocytes.  E5  is  a  highly 
hydrophobic protein made up of 83 amino acids that participates to viral DNA replication 
along with E1, E2 and E4 proteins. His Its expression induces several cellular changes. 
Indeed, E5 enhances the signal of growth factors (Crusius  et al.,  1998) activates MAPK 
pathway and down-regulates MHC class I and class II (Ashrafi et al., 2005). Specifically, 
E5: (i) activates the EGF receptor to promote cell proliferation; (ii) enhances the activity of 
transcription  factors,  such  as  c-jun  and  c-fos  thereby  favoring  cellular  mitosis;  (iii) 
inactivates p21; (iv) prevents apoptosis resulting in DNA damage: (v) prevents transport of 
the major histocompatibility complex (MHC) class I and class II. Recent works proved that 
E5 contributes to hyperplasia, regulates growth and invasion in cervical cancer cell lines 
and promotes cervical carcinogenesis in conjunction with E6 and E7 (Genther et al., 2005; 
Maufort  et  al.,  2010).  A study of Kabsch conducted,  in  2002,  indicates  that  E5 could 
inhibit apoptosis, forcing the cell to remain in a continuous proliferative state. 
E6 and E7 are the two oncoproteins of High Risk HPVs. These two viral proteins 
are essential  to induce and maintain cell transformation because they interfere with the 
normal controls of cell cycle and apoptosis. E6 is one of the first proteins to be expressed 
during HPV infection. This protein is formed by 150 amino acids with a molecular weight 
of 18 kD. Typically, E6 protein of High Risk HPVs is located in the nucleus and has no 
intrinsic enzymatic activity. E6 is involved in different cellular pathways, which involve a 
large number of different proteins: transcription factors, pro-apoptotic proteins, proteins 
involved in the formation and maintenance of cellular architecture, polarity and adhesion, 
and factors involved in DNA replication and repair. (Zur Hausen, 2002). E6 protein binds 
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to tumor suppressor protein p53, its principal target, thereby leading to p53 degradation 
(Scheffner  et al., 1990; Werness et al., 1990). p53 plays a key role in apoptosis and cell 
cycle  regulation,  through  several  mechanisms:  (i)  it  induces  apoptosis  in  the  case  of 
irreparably damaged DNA;  (ii)  it  activates  p21 (an inhibitor  of cyclin/cyclin-dependent 
kinase complex, cdk) consequently holding cell cycle at the G1/S regulation point on DNA 
damage recognition and finally blocking cell growth (Vogelstein et al., 2000). Therefore, 
functional inactivation of p53 by E6 results in G1/S and G2/M deregulation of cell cycle 
control leading to abnormalities in DNA replication and genomic structure. The carboxyl 
(C)-terminal of E6 protein carries a short sequence that interacts with a specific set of PDZ 
domains included in several human proteins (Scott and Klingelhutz, 2014). PDZ domains 
(an acronym from the initial of the proteins PSD95, DLG, and ZO1 on which they have 
been  identified)  are  small  domains  that  bind  to  peptide  ligands  through  a  consensus 
sequence XX(S/T/Y)X(V/L/M) located on target proteins. The PDZ protein family present 
a conserved domain that is often found in proteins located in the areas of contact between 
cells,  such as  tight  junctions  between epithelial  cells  or  neural  cell  synaptic  junctions. 
Furthermore,  PDZ  proteins  are  implicated  in  signal  transduction  and  polarity.  The 
members of PDZ protein family (MUPP-1, and hDlg, hSCRIB, MAGI-1, -2 and -3, GIPC, 
PATJ, PTPN3 and PSD95) bind the C-terminus of the protein E6 of oncogenic HPVs and 
are  subsequently  degraded  in  a  proteasome  dependent  manner  (Gardiol  et  al., 1999; 
Glaunsinger  et al., 2000; Nakagawa and Huibregtse, 2000; Massimi  et al., 2004). As a 
consequence  of  the degradation  of  PDZ family  proteins,  cellular  contact  mediated  by 
adherence junctions is lost with a consequent lack of cell polarity. These alterations were 
observed in High Risk HPV-associated transformed cells. 
E6 protein is also able to induce cell immortalization via telomerase activation and 
specifically activating the expression of the catalytic subunit of telomerase, i.e. telomerase 
reverse  transcriptase  TERT.  Telomerases  are  RNA-dependent  polymerases  that  add 
telomere  repeats  to  the ends of chromosomes  (Klingelhutz  et  al.,  1996;  Kiyono  et al., 
1998; McMurray and McCance, 2003; Howie  et al., 2009). They are ribonucleoproteins 
made up by RNA and a protein component,  which is  the reverse transcriptase subunit 
TERT. This subunit catalyzes the addition of deoxynucleotides in a TTAGGG sequence to 
the  ends  of   telomeres  (Shampay  and  Blackburn,  1988).  Thereby  preventing  the 
degradation  of the chromosomal  ends during DNA replication.  Both proliferative  stem 
cells and cancer cells express human TERT (hTERT). The expression of hTERT allows 
telomerase activity and suppression of cell senescence in germ cells. The E6 of some HPV 
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types is able to activate the TERT promoter and this mechanism is strongly associated with 
cancer (Van Doorslaer and Burk, 2012). Even though the exact molecular mechanism of 
promoter  activation  is  still  unclear,  it  probably  involves  E6AP  binding  (Gewin  and 
Galloway,  2001).  Furthermore,  E6  activates  the  transcription  of  hTERT  through  the 
transcription factor c-myc (Veldman  et al.,  2001) that displaces the USF transcriptional 
repressor  from  the  E  box  in  the  TERT  promoter  (McMurray  and  McCance,  2003). 
According to other models, E6 and E6AP bind to a repressor of TERT transcription called 
NFX1-91,  inducing  its  degradation.  The  interaction  between  E6-E6AP  and  NFX1-91 
allows myc to bind to the hTERT promoter and activates it (Gewin  et al., 2004). As a 
consequence of the interaction with E6-E6AP, NFXI-91 is ubiquitinated and degradated, 
thereby removing transcriptional repression at the TERT promoter. Conversely,  a splice 
variant  of  NFX1  referred  to  as  NFX1-123  is  unable  to  interact  with  E6  and  hence 
transcriptional repression is kept despite HPV infection (Katzenellenbogen  et al.,  2007). 
Furthermore,  NFX1-123 stabilizes  TERT transcripts  in HPV-16 E6 expressing cells  by 
binding to poly-(A) binding proteins (Katzenellenbogen et al., 2007; Katzenellenbogen et  
al., 2009).  Interestingly, E6 is able to bind directly TERT proteins, (Liu et al., 2009) even 
though the biological consequences of this interaction are still unknown (Liu et al., 2009).
HPV E7  is  a  phosphoprotein  made  up  of  100  amino  acid  residues  that  is  not 
encoded by all papillomaviruses. E7 is composed by three domains: conserved region (CR) 
1, CR2 and CR3. The E7 amino terminus region contains two regions corresponding to the 
small  portion  of  CR1  and  nearly  the  entire  CR2,  whose  sequence  is  similar  to  the 
adenovirus (Ad) E1A (Phelps et al., 1988). The CR1 and CR2 domains are separated by a 
non-conserved  sequence  of  variable  size  and  amino-acidic  composition.  The  CR3  is 
located  at  the  carboxyl  terminal  that  contains  a  zinc-binding  site  important  for 
dimerization. Such a site is made up by two CXXC domains separated by 29-30 amino 
acid residues (Barbosa et al.,  1989; McIntyre et al., 1993). When one or both the cystein 
residues of one zinc-binding site is mutated,  the virus is no longer able to  immortalize 
human keratinocytes in the dermis (HFK) and transform rodent cells (Dyson et al., 1989). 
E7  could  presents  post-translational  modifications.  Indeed,  E7  contains  a  consensus 
phosphorylation site for: (i) protein kinase C (PKC) on threonine 7 in the CR1 homology 
domain (Liang et al., 2008); (ii) casein kinase II (CKII) in the CR2 domain (Firzlaff et al.,  
1989; Barbosa  et al.,  1990); (iii)  unknown kinase in CR3 domain (Massimi and Banks, 
2000).  E7  can  be  either  carboxyl  terminally  polyaminated  or  amino  (N)-terminally 
ubiquitinated and subsequently degradated via proteasome (Reinstein et al., 2000; Jeon et  
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al.,  2003).  This  oncoprotein  is  usually  located  in  the  nucleus,  but  can  be  potentially 
shuttled  between  the  two  cellular  compartments,  thanks  to  nuclear  export  sequences 
(Knapp et al., 2009). E7 interacts with several cellular proteins: transcription factors and 
proteins that remodel chromatin, negative regulators of the cell cycle, and components of 
the  innate  immune  response.  As  previously  reported,  E7  has  oncogenic  activity  as  it 
efficiently immortalizes human keratinocytes via the combined action with E6 (Felsani et  
al., 2006). In addition to that, E7 binds pRb and other members of Rb family: p107 and 
p130 (Dyson et al., 1989; Davies et al., 1993). E7 associates to pRB through the conserved 
LXCXE sequence motif within CR2 domain (Dyson et al., 1989). pRb is a nuclear tumor 
suppressor phosphoprotein belonging to the pocket protein family, whose members have a 
interacting  region  with  various  proteins  (Korenjak  and  Brehm,  2005).  pRb  prevents 
excessive  cell  growth  by  inhibiting  cell  cycle  progression  and  can  be  considered  a 
“molecular  brake”  of  the  transition  from  G1  to  S  phase.  pRb  regulates  cell  cycle 
progression  through  the  interaction  with  E2F/DP,  a  dimer  of  E2F  protein  and  a 
dimerization partner (DP) protein (Wu et al., 1995) that pushes the cell cycle into S phase 
(Funk  et  al., 1997).  The active  form of  pRB normally  binds  and inactivates  E2F/DP, 
blocking cell  cycle  in G1 phase.  Furthermore,  the complex pRb-E2F/DP interacts  with 
several  chromatin  remodeling  enzymes  such  as  acetylases  and  methylases,  thereby 
silencing numerous promoter of genes involved in the progression from G1 to S phase. On 
the contrary, when the cell is ready to divide, Rb is inactivated through phosphorylation, 
allowing the progression from G1 to S phase. The other two members of retinoblastoma 
family that interact with E7 (p107 and p130) are involved in the control of the different 
phases of the cell cycle. Specifically,  p130 has a regulatory function during the G0/G1 
phase, while p107 is active in the G1/S transition.  E7 is able to bind p107 and p130, 
allowing  cell  progression  from  G1  to  S  phase  and  enhancing  cellular  proliferative 
characteristics (Dyson  et al., 1989; Howie  et al., 2009). E7 is able to interact with the 
cyclin-dependent kinase, CDK2 dependent cyclin A and E that normally regulate cell cycle 
(Arroyo et al., 1993). Furthermore, it associates to inhibitors of cyclin/cdk complex as p21 
and p27, thereby blocking their inhibitory action and fostering the activity of the complex 
cyclin/cdk (Funk  et al., 1997). p16INK4a is an inhibitor of cyclin/cdk complex, whose 
overexpression  normally  induces  cycle  arrest.  E7  counteracts  the  inhibitory  role  of 
p16INK4a  through  mechanisms  that  have  not  been  completely  clarified  yet.  For  this 
reason, p16INK4a was considered as a molecular marker for the CIN pre-cancerous lesions 
(Razmpoosh et al., 2014). Furthermore, E7 is able to bind histone deacetylases (HDACs), a 
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class of enzymes that remove acetyl groups (O=C-CH3) from the ε-N-acetyl lysine amino 
acid on the histones and increase their ability to bind to DNA, thereby enhancing genetic 
transcription.  The  interaction  between  E7  and  HDACs  causes  chromatin  packing  and 
consequently blocks transcription. Since pRb normally binds and recruits HDAC at level 
of E2F inducible promoters, E7 can prevent histone deacetylation also in an indirect way, 
i.e.  through  the  inhibition  of  pRb  (Brehm  et  al., 1999).  Furthermore,  in  the  case  of 
persistent HPV infection, HDACs recruitment allows E7 to silence specific genes, such as 
interferon regulatory factor 1 (IRF1), whose expression is important in immune response 
(Park  et al., 2000). Since the viral genome is unable to remain permanently in episomal 
form when a mutation in the E7-HDAC binding site of E7 is induced (Longworth and 
Laimins,  2004),  it  has  been  deducted  that  the  association  with  HDAC  allows  E7  to 
maintain the viral DNA in episomal form. The molecular mechanism of such an interaction 
is still unclear, but it has been proposed that HDAC directly deacetylates of E2F, causing 
loss  of  function.  Another  important  action  of  E7 is  the  transactivation  of  the  enzyme 
phosphatase  Cdc25,  which  allows  the  dephosphorylation  and  activation  of  complex 
cyclin/cdk and is required for cell cycle progression (Jinno et al., 1994). Another capacity 
of E7 is the ability to induce genomic instability. In fact, several HPV-positive cancer cells 
contain different aneuploidies, indicating that changes in the number of chromosomes are 
important  events  in  tumor  progression.  The  presence  of  E7  is  sufficient  to  induce  an 
abnormal  increase  in  the  number  of  chromosomes  in  primary  human  keratinocytes 
(Duensing  et al.,  2000). Mutated E7 proteins that do not bind or degrade pRb, but are 
associated with p107, induce centrosome abnormalities during cell division (Duensing and 
Munger, 2003). These anomalies are also observed in cells lacking p53 and pRb and in 
embryonic fibroblasts of knock-out mice for pRb, p130 and p107. It has been speculated 
that  a  combination  of  family members  of pRb or other  factors  can induce  centrosome 
abnormalities during HPV infection (Duensing and Munger, 2003).
 The late proteins L1 and L2 have a structural function. L1 is the major viral capsid protein 
common  to  all  the  HPV protein.  L1 self-assemble  into  72  pentamers  and is  the  most 
exposed region of the capsid and the target of the majority of neutralizing antibodies. L2 
protein is highly variable among different types of HPV. This viral protein plays mainly 
regulatory and structural. In fact, it presents a nuclear localization signal and it is involved 
into the selective viral DNA encapsidation.
13
The life cycle of HPVs in uterine cervix 
HPV  infections  are  mainly  common  in  keratinocytes  of  the  skin  or  mucous 
membranes  presenting  pluristratified  epithelium,  the  only  tissue  in  which  they  can 
replicate. In particular, HPV infection starts with the initial contact of the virus with micro-
abrasions of the cutaneous or mucous membranes that expose segments of the basement 
region of the pluri-stratified epithelia, composed by stem elements (figure 1, A; Figure 4). 
Following the same process, genital HPV attack the uterine cervix, whose covering surface 
is thin and hence particularly susceptible to suffer from micro-abrasions, making it even 
more vulnerable to infection. As far as we know, the virus enters in the basal cells through 
endocytosis, even though the exact mechanism (classical endocytosis or receptor-mediated 
endocytosis) is still unclear. Presumably the heparan sulfate proteoglycans, located at the 
cell surface and in the extracellular matrix, mediate the initial phase of cell infection (Joyce 
et al., 1999; Patterson et al., 2005). As for other viruses, (Chung et al., 1998; Summerford 
et al., 1999) it seems that secondary receptors as efficient as the integrin receptor α4β6 are 
needed  for  HPV  infection  (Evander  et  al.,  1997;  Bossis  et  al.,  2005).  After  receptor 
recognition, the process of endocytosis occurs through clathrin-coated vesicles. After the 
entrance of the virus into the cytoplasmic compartment (Culp and Christensen, 2004), the 
capsid protein is disassembled in the lysosomes and the viral DNA is transferred into the 
nucleus through the minor capsid protein L2 (Day et al., 2003). The viral DNA remains in 
episomal  form in  the  nucleus  in  the  number  of  10-100 copies/cell  equivalent  and this 
process does not usually cause cytological abnormalities (Schiller et al., 2010). HPV early 
genes E1/E2 are expressed at low levels in the nucleus and trigger the replication of the 
viral genome, which is almost completely mediated by the replicative machinery of the 
host  keratinocyte  (Figure  4).  The  life  cycle  of  HPV is  intimately  associated  with  the 
proliferative  activity  and  differentiating  status  of  the  host  keratinocyte.  In  fact,  quick 
cellular replication is necessary for an increased viral progeny. E2 protein activates and 
controls the expression of E6 and E7 that stimulate the host cell to proliferate, thereby 
stimulating cell growth.
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Figure 4. HPV life cycle. Graphical representation of the key events in HPV life cycle:  
from the first interaction with the basal layer by the virions to the DNA replication, viral  
gene expression and viral release.
Furthermore, E6 and E7 proteins induce a block of cell cycle progression keeping 
the  cell  in  an  undifferentiated  state.  The  final  effect  is  an  increased  proliferation  of 
undifferentiated and infected keratinocytes (Doorbar et al., 2012). The viral cycle follows 
the  natural  maturation  of  the  epithelium,  where  basal  keratinocytes  progressively 
differentiate  while  moving towards the most  superficial  layers.  In the intermediate  cell 
layers,  viral DNA replication stops and the expression of E4 and E5 early genes starts 
(Figure 4, http://www.clinsci.org/cs/). The proteins transcript of E4 activate the expression 
of the late genes L1 and L2, while and proteins transcript of E5 encapsidates the viral DNA 
within  the  virion  (Doorbar  et  al.,  2012).  The  virus  is  completely  assembled  in  the 
squamous cells of the upper layer of the pluri-stratified epithelium, where the keratin is 
destroyed and virions are released by dead cells (Figure 4). The infectious process is slow 
as it takes about 12–24 hours for the initiation of transcription and the final passage of life 
cycle is the exfoliation of superficial keratinocytes and subsequent release of HPV virions 
into the surrounding cervix environment (Doorbar et al., 2012). The complete life cycle of 
HPV from the first interaction with the basal layer to the viral release, requires about 6-12 
weeks.
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HPV and cell proliferation
During the full replicative cycle of low-risk HPV the genome remains in episomal 
form and the production of mature viral progeny occurs. On the contrary, during high-risk 
HPV infections viral  DNA is integrated into the DNA of the host cell.  This molecular 
mechanism has a double effect: it decreases viral progeny on the one hand and it increases 
proliferative capacity in the host cell on the other hand. Indeed, the integration occurs at 
the level of the E2 ORF, blocking the repressive action of E2 on viral oncoproteins E6 and 
E7 and leading to uncontrolled expression. As recently reported, E6 and E7 stimulate cell 
cycle progression by inhibiting the activity of important regulatory proteins of the cycle, 
p53 and pRb, with well known molecular mechanisms (Munger  et al., 1989; Sheffner  et  
al., 1990). E5 seems to be involved in the stimulation of cell proliferation. In fact, it can 
inhibit apoptosis and lead the cell to a high proliferative status.
HPV and tumorigenesis
A crucial aspect of the replicative cycle of cervical high-risk HPVs is the possibility 
to induce persistent infections. As previously reported, the integration of viral DNA into 
the DNA of  the host cell  causes  the disruption of E2 gene sequence and leads  to  the 
uncontrolled and continuous production of viral oncoproteins E6 and E7. Consequently, 
the epithelial cells that express E6 and E7 have a growth advantage compared to those that 
contain  the  viral  DNA in  episomal  form.  This  is  the first  mechanism in the  multistep 
process  of  cervical  neoplastic  transformation.  E6,  E7  and  E5  are  critical  for  the 
tumorigenic process, as they stimulate cell proliferation, induce cell survival and modulate 
keratinocytes  differentiation,  as  confirmed  by  experimental  models.  In  fact,  when  the 
expression of E6 and E7 is inhibited in cultured transformed cells the malignant phenotype 
is reverted, while the activation of E2 in  in vitro experiments blocks cell proliferation in 
cervical SCC cell lines (Goodwin et al., 1998; Jiang and Milner, 2005). During high-risk 
HPVs infection,  the tumorigenic  process  changes  the histological  characteristics  of the 
cervical squamous pluri-stratified epithelium. However, the viral DNA is present only in 
the episomal form and the expression levels of oncoproteins E6 and E7 are relatively low 
(Schiller et al., 2010). This phase is generally referred to as CIN1 lesion. Conversely, when 
the viral DNA begins to integrate in shuffle mode and becomes equally available in the 
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episomal  and  integrated  form,  the  cervical  pre-neoplastic  lesion  acquires  tumorigenic 
potential  (CIN2).  Finally,  cervical  keratinocytes  of  CIN3 lesions  are  no longer  able  to 
regulate  their  own  proliferative  and  differentiation  capacity,  due  to  the  uncontrolled 
expression of E6 and E7. Epidemiological and experimental data indicate that the presence 
of High-risk  HPVs  in  cervical  keratinocytes  is  necessary  yet  not  sufficient  to  induce 
cervical  SCC.  Indeed,  other  genetic  and epigenetic  events  would  be  implicated  in  the 
multifactorial  process  of  neoplastic  transformation  (Zur  Hausen,  2002),  justifying  the 
presence of several functional and structural abnormalities of both oncogenes and tumor 
suppressor genes as well as epigenetic modifications in cervical SCCs. As to the proto-
oncogenes,  cell  mutations  and/or  gene  amplification  have  been identified  in  the  genes 
encoding for the subunits of PIK3CA, RAS, MYC, ErbB2 and cIAP1 (Zhang et al., 2002; 
Imoto et al., 2002; Bertelsen et al., 2006). As to the tumor suppressor genes, loss of PTEN, 
CADM1 and NOTCH seems to be associated with tumor progression (Cheung et al., 2004; 
Overmeer et al., 2008; Vande and Klingelhutz, 2013). The epigenetic deregulation and its 
role in cervical pre-neoplastic CIN progression or in SCC will be dealt in detail  in the 
following chapter.
EPIGENETIC AND CANCER
It  is well known that epigenetic alterations,  i.e.  improper DNA methylation and 
histone modification, are strongly involved, as other molecular phenomena, like genetic 
mutations or gene expression changes, in a cell’s transformation to cancer (Novak, 2004). 
Furthermore,  the DNA methylation  and histone modifications  defects  could be operate 
alone  or  in  concert  with  several  other  molecular  alterations  involved  in  cancer 
development.  
Epigenetics can be defined as the study of all heritable chemical modifications that 
affect the phenotype without altering the genotype. Indeed, it is defined as ‘‘the study of 
mitotically and/or meiotically heritable changes in gene function that cannot be explained 
by changes in DNA sequence’’ (Russo et al., 1996). Furthermore, epigenetics modification 
may have short- or long-term and even trans-generational effect. Epigenetics modification 
are well-established and common phenomena in all cells and are involved in the regulation 
17
of gene expression.  At the  basis  of the  epigenetics  process there are  the regulation  of 
chromatin remodeling and regulation of gene expression that are accomplished through 
two related  mechanisms:  DNA methylation  and posttranslational  histone modifications. 
From a biological standpoint, epigenetics modifications are phenomenon that plays a key 
role in a diversity of processes, such as embryonic development, immune system response, 
infertility and cancer development. However, aberrant epigenetic modifications may have 
the same negative effect of a gene mutation, because the expression of the DNA is altered. 
Consequently,  aberrant epigenetic modifications may be associated,  or induces, disease. 
While the genetic code is considered static, i.e. it is the same in each cell for the entire life 
of the organism, the epigenetics phenomena are dynamic, tissue-specific and provides to 
change the phenotype because of various factors such as environmental factors (Li et al., 
2006).  This  dynamic  state  may  suggest  the  possibility  of  reversibility  of  epigenetic 
changes, and then a possible therapeutic target for a certain number of diseases. (Egger et  
al., 2009)
Aberrant  CpGs  methylations,  hypo-  and  hypermethylation,  have  long  been 
associated with diseases and cancer.  DNA methylation is a biochemical process based to 
the addition of a methyl group to the S-adenosyl-methionine to the 5’ position of cytosine 
belonging  to  CpG  DNA  dinucleotide  (Biermann  and  Steger  2007).  This  activity  is 
mediated by DNA methyltransferases (DNMTs) family enzymes. Specifically, the family 
of enzimes DNMT1 is involved in the maintenance of methylation patterns (Bestor et al., 
1988); whereas, enzymes DNMTs 3a and 3b (Okano et al., 1999) are required for de novo 
methylation activity (Lei et al., 1996; Okano et al., 1999). Another protein, DNMT3L, is 
homologous  to  DNMT3s,  but  has  no  catalytic  activity  and  assists  the  DNMTs  by 
increasing their ability to bind DNA and stimulating their activity (Chedin  et al., 2002; 
Suetake et al., 2004). Takai and Jones formulated the accepted definition of a CpG island 
as a 500, or higher, base pair segment of DNA with a G+C equal to, or greater than, 55% 
and with a CpG frequency of at least 0.65 of the statistically expected value (Takai and 
Jones,  2002). In mammals  70% to 80% of CpG cytosines are methylated (Jabbari  and 
Bernardi  2004).  CpG  islands  are  located  preferentially  in  high  concentrations  within 
promoters genes (Bird  et al.,  1995) with a frequency about 40% (Fatemi  et al.,  2005), 
indicating that they are involved in the regulation of gene expression (Deaton and Bird, 
2011).  Indeed,  DNA hypomethylation  in  CpG islands  correlates  with  gene  expression 
(Biermann and Steger, 2007), whereas DNA methylation in CpG islands is associated with 
trascriptional  repression  (Deaton  and  Bird,  2011).  Hypermethylation  in  CpG  islands 
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located at  gene promoter  region cause gene suppression because:  (i)  DNA methylation 
itself prevents binding of transcriptional factors (Choy et al., 2010); (ii) methylated DNA 
is  bound by methyl-CpG-binding  domain  proteins  (MBDs)  (Nan  et  al.,  1993),  which, 
subsequently recruit other factors involved in gene expression inhibition (Illingworth and 
Bird, 2009; Thomson et al., 2010);
In  general,  these  epigenetic  modifications,  causes  defective  gene  expression, 
improper condensation and chromosomal instability (Attila and Lorincs, 2014). In cancer 
cells, both of these alterations could coexist in concert or alone. As previously reported, 
CpG islands are typically located within, or close to, gene promoter and are involved in 
gene  expression  regulation.  Whereas  CpG  islands  preceding  tumor  suppressor  gene 
promoters  are  generally  unmethylated,  in  cancer  cells  it  is  possible  that  an  abnormal 
increase  of  methylation  level  at  this  region  induce  gene  silencing.  Indeed, 
hypermethylation  of  tumor  suppressor  gene  promoters  is  often  associated  with  the 
silencing of those genes. The tumorigenic process is induced when genes that regulate the 
cell cycle are silenced, allowing cells to increase their proliferative capacity and reproduce 
uncontrollably (Esteller, 2007). Two important genes that acquire hypermethylation were 
two cell-cycle inhibitor referred to as p16 and p15 in different types of cancer (Viet et al., 
2007).  Various  genes  involved  in  DNA  repair,  such  as  O-6-methylguanine-DNA 
methyltransferase (MGMT), undergo defective methylation in many types of carcinomas 
(Esteller et al., 1999; Weller et al., 2010). Furthermore, another DNA-repair gene found to 
be  hypermethylated  is  MLH1.  This  gene  was  detected  whit  this  defective  epigenetics 
aberration  in  gastric  cancer  (Li  et  al., 2014).  Others  suppressor  genes  known  to  be 
hypermethylated during cancer progression were: RB, Cyclin-dependent kinase inhibitor; 
the Von Hippel–Lindau tumor suppressor gene VHL; and E-cadherin, a calcium-dependent 
cell-cell adhesion glycoprotein (Greger et al.,1989; Santini et al., 2001). Typically, during 
cancer development, while hypermetilation generally occurs in a single molecular target, 
DNA  hypomethylation  is  a  general  phenomenon.  Genomic  instability  is  the  principal 
consequence,  but  sometime  transcriptional  activation  of  oncogenes  may occur.  Indeed, 
aberrant hypomethylation of CpG islands located at proto-oncogene promoters could lead 
to an increase of expression of these genes. In normal cell, repetitive genomic sequence, 
such  as  LINE,  SINE,  IAP  and  Alu  elements  are  highly  methylated.  These  genomic 
sequences  ensure  genomic  integrity/stability  and  improper  hypometylation  phenomena 
could induce undesired mitotic recombination. Indeed, loss of DNA methylation in SAT2 
(juxtacentromeric  satellite  2) and SATα (centromeric  satellite  α) was detected in breast 
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cancer and may contribute to progression of ovarian cancer (Widshwendter  et al., 2004). 
DNA loss of methylation of individual gene is rather in common. Indeed, frequently, most 
of promoter regulatory region are under this epigenetic control, belong to tissue specific 
genes. For instance, a cancer/testis (CT) antigens, expressed in normal condition in adult 
male testis, are epigenetically and aberrantly activated in various types of human cancers 
(Caballero  and Chen,  2009).  Furthermore,  in  colorectal  cancer  and melanoma,  the  CT 
antigens MAGE are reactivated by promoter hypomethylation (Weber et al., 1994). 
High-risk HPVs and epigenetics deregulation in cancer
The  multifactorial  process  of  cervical  SCCs  high-risk  HPVs  induced,  includes, 
among the various aspects, epigenetic changes in the host genome. The apoptotic pathway 
presents  numerous  genes,  which  epigenetic  aberrations  are  involved  with  the  onset  of 
cervical  SCCs.  The  gene  coding  two  members  of  tumor  necrosis  factor  receptor 
superfamily, referred to as decoy receptors (DcR1/DcR2) can be the target for abnormal 
methylation that leads to their silencing in cervical SCCs, suggesting that cervical cancer 
cells  may  obtain  a  growth  advantage,  probably  due  to  the  down-regulation  of  decoy 
receptor DcR1/DcR2 (Van Noesel  et al., 2002; Shivapurkar  et al., 2004). Interestingly, 
despite  cervical  SCCs  show  down-regulation  of  hTERT  mRNA,  a  study  has  found  a 
correlation between reduced expression, and catalytic subunit activity, with hTERT gene 
promoter demethylation (Guilleret and Benhattar, 2003). p73, a member of the p53 family,  
involved in cellular response to DNA damage induced by radiation and chemotherapeutic 
agents, presents two independent promoters that have opposite activities. One of this two 
promoters presents within the exon 1, is rich in CpG dinucleotides and its transcriptional 
silencing through hypermethylation represents a mechanism for inactivation of this gene in 
cervical SCCs (Liu  et al., 2004). As previously reported, a lot of number of cell cycle-
related genes is deregulated during cancer development. Aberrant methylation of the p16 
gene promoter occurs in situ as well as in invasive tumors with a frequency of ranged 
between  10-100%  (Nakashima  et  al.,  1999).  Furthermore,  p16  hypermethylation  is 
progressively  most  frequent  during  CIN  pre-cancerous  lesions  progression.  Indeed  is 
present in 17.6% of CIN I, 42.1% of CIN II, 55.0% of CIN III, and 65.0% of invasive 
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cancers (Huang et al., 2011). Two other genes cycle-related genes epigenetically involved 
in cervical SCCs onset and progression are CCNA1 and the fragile histidine triad (FHIT). 
The  CCNA1 gene  encodes  Cyclin  A1,  which  regulates  the  cell  cycle.  CCNA1 
downregulation  due  to  promoter  hypermethylation  was  detected  in  60% and 93.3% of 
microinvasive  cancers,  and invasive  cancers,  respectively (Yang  et  al., 2010).  FHIT is 
another protein involved in cell cycle regulation and apoptosis. Epigenetic silencing of this 
gene  by  promoter  hypermethylation  is  common  in  cervical  cancer  (Ki  et  al., 2008). 
Furthermore, the signal transduction pathway Wnt, named for its most upstream ligands, 
the Wnts, is epigenetically deregulated during cervical SCC development. In this pathway 
were detected promoter aberrant methylations in PTEN (Cheung et al., 2004), E-cadherin 
(Widschwendter  et al., 2004) and APC (Virmani  et al., 2001) in various cervical SCCs 
cases. Two genes belonging to the Fanconi anemia (FA)-BRAC pathway referred to as 
BRCA  and  FANCF  present  aberrant  methylation  in  their  promoter  in  cervical  SCCs 
(Marsit  et al., 2004; Narayan et al., 2003). Furthermore, in a study conducted in patients 
with  SCC,  BRCA1  promoter  hypermethylated  cases  present  a  frequency  of  6.1%,  in 
invasive SCCs, whereas FANCF hypermethylation rate was 30%. Thus, hypermentilation 
of these genes was mutually exclusive in the analyzed cases, suggesting the important role 
of  epigenetics  aberrations  in  this  pathway  for  cancer.  (Narayan  et  al.,  2004).  Other 
molecular  pathways  that  have  genes,  which  promoter  carries  epigenetics  deregulations 
include:  mismatch  repair,  metastasis/cell  death,  cell  differentiation  and  DNA  repair 
(Narayan et al., 2003; Virmani et al., 2001).
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MOLECULAR STUDIES OF CIN PROGRESSION
The  molecular  bases  involved  in  the  pre-cancerous  CIN lesions  progression  to 
cervical SCC were previously investigated in different studies. These studies were carried 
out at both tissue and cellular level using microarray analysis or HPV DNA transfection 
assays, respectively. 
In order to compare gene expression signature on biopsies from cervical SCC with 
normal tissues, different studies were performed using microarray technique. (Cheng et al., 
2002; Chen et al., 2003; Wong et al., 2003; Rosty et al., 2005; Wong et al., 2006; Chao et 
al.,  2006).  However,  in  all  these  studies  have  not  been  investigated  the  molecular 
mechanisms  involved  in  the  progression  of  CIN  lesions  to  the  cervical  SCC.  These 
mechanism were subsequently investigated in other works when were used, in addition to 
cervical SCC and normal tissues, CIN biopsies as well (Gius  et al., 2007; Arvantis and 
Spandidos, 2008; Song et al., 2008; Rajcumar et al., 2011). A work conducted by Gius and 
colleagues  shows  that  proproliferative/immunosuppressive  genes,  such  as  p16INK4a, 
KIF23  and  CENPF are  up  regulated  in  CIN1  lesions,  probably  due  to  the  epithelial 
response  to  human  papillomavirus  infection,  while  proangiogenic  stromal/epithelial 
interaction genes, such as HINT1, TAGLN and TBX19 and proinvasive genes, such as 
DSG3, MMP3 are mainly up-regulated in CIN2 and CIN3 lesions,  respectively.  These 
results suggest a cooperative signaling interaction between stroma and tumor cells. Finally, 
the signature pattern detected in CIN3 and SCC probably represents epithelial tumor cell 
overcrowding (Gius et al., 2007). 
Microarray studies were performed on biopsies of tumor and normal tissue. This 
study model may affect the actual gene expression profile of the type of cell under study, 
as keratinocytes, in this case. Such a problem has to be ascribed to tissue samples - in 
particular cervical CIN or normal tissue samples - that contain a significant number of 
stromal cells and contaminants derived from the host immune cells, such as monocytes, 
dendritic cells and lymphocytes. 
In vitro HPV-transfected human skin keratinocytes represent good models to mimic 
the molecular  and morphological  characteristics  of cancerous cells  (Pirisi  et al.,  1987;; 
Zyzak et al., 1994; Creek et al., 1995; Borger et al., 2000; Akerman et al., 2001; Chang 
and Laimins, 2000; Nees et al., 2001; Oh et al., 2001). In vitro models of HPV-transfected 
cells  showed loss  of  differentiation,  overexpression  of  EGF receptor  and resistance  to 
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TGF-beta-induced  growth  inhibition  (Pirisi  et  al.,  1988).  Several  studies  have  applied 
microarray technology to this model with the aim of identifying the molecular processes 
involved  in  HPV-induced  transformation  and  tumor  development  (Ruutu  et  al.,  2002; 
Duffy  et  al.,  2003;  Kravchenco-Balasha  et  al., 2009).  However,  HPV-transfected 
keratinocytes may not mirror the actual in vivo situation because they do not derive from 
the uterine cervix,  but from other parts of the body.  Moreover,  keratinocytes  were not 
naturally infected by high-risk HPVs. Consequently, the molecular pathways detected in 
this model could be different from those involved in HPV induced progression to cervical 
SCC. 
Only few gene-expression studies have been performed on cervical keratinocytes 
that were naturally infected with HPV, i.e.  in vitro neoplastic HPV-keratinocytes derived 
from CIN lesions (Gray  et al., 2010). In those studies, the gene expression profile was 
investigated in HPV16-infected keratinocytes derived from low-grade CIN1 lesions (Gray 
et al., 2010). A work of Nees and colleagues used, as a study model, primary cultures of 
ectocervical  keratinocytes  obtained from cervical  tissue from hysterectomies.  The cells 
used were infected with retroviruses expressing E6 and E7 genes of HPV16 (Nees et al., 
2001).  In  1989 Stanley and colleagues  set  up a  human  cervical  keratinocyte  cell  line, 
referred to as W12, from a low-grade cervical lesion histologically diagnosed as CIN1. 
This keratinocyte cell line represented a good model to study the natural history of cervical 
neoplasia.  In  fact,  the  same  model  was  used  to  identify  groups  of  genes  that  carried 
expression  changes  due  to  HPV-16  integration  (Alazawi  et  al.,  2002).  Santin  and 
colleagues analyzed gene expression on  in vitro cultures of cervical keratinocytes using 
microarray  assay.  Even  though  cultured  keratinocytes  did  not  derive  from  CIN  pre-
cancerous lesions, the study was conducted on 15 primary cervical cell lines: 11 HPV-16 
or HPV-18 positive cervical  SCC primary cultures  and 4 cell  lines  of normal  cervical 
keratinocytes (Santin et al., 2005).
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OBJECTIVE AND AIMS 
OF THE STUDY
Overall,  the  main  objective  of  my  study  was  to  investigate  the  molecular 
mechanisms occurring in neoplastic progression of CIN2 and CIN3 cervical pre-cancerous 
lesions. To this purpose, HPV16-CIN2 and HPV16-CIN3 keratinocytes derived from high-
grade CIN2 and CIN3 pre-cancerous lesions were investigated by microarray analysis and 
DNA methylation of gene promoters. Aims of this study were:
I
To set up a cell culture protocol able to derive pre-neoplastic and normal cervical 
keratinocytes from small tissue fragments of naturally high-risk HPV-infected CIN2 and 
CIN3 lesions and normal uterine cervix, respectively. Cultures of CIN and normal cervical 
keratinocytes  were  stained  with  immunofluorescence  technique  in  order  to  investigate 
expression of epithelial and cervical markers.
II
To  investigate  the  gene  expression  profile  of  HPV16-CIN2  and  HPV16-CIN3 
keratinocytes.  To  this  purpose,  HPV16-CIN2  and  HPV16-CIN3  keratinocytes  and  the 
corresponding normal cervical keratinocytes were subjected to microarray analysis, Real-
Time Quantitative RT- PCR, and Immunohistochemistry analysis.
III
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To analyze  the  mRNA expression levels  and DNA methylation  status  of  target 
genes in  HPV16-CIN2 and HPV16-CIN3 keratinocytes. To this  purpose,  HPV16-CIN2 
and HPV16-CIN3 keratinocytes and the corresponding normal cervical keratinocytes were 
subjected to Real-Time Quantitative RT- PCR, and bisulfite sequencing analysis.
MATERIALS AND METHODS
CERVICAL UTERINE SPECIMENS 
Small tissue fragments (2-3 mm3) were taken from CIN biopsies, CIN2 or CIN3 
pre-cancerous  lesions,  after  surgery  excision.  The  corresponding  surrounding  normal 
tissues were also provided. The patients had undergone electrosurgical conisation under 
colposcopic examination using 5% acetic acid and Lugol’s iodine solution, which stains 
the pathologic tissue with a white color, whereas stains normal tissue brown (Stafl and 
Wilbanks,  1991).  CIN  and  normal  specimens  were  selected  and  divided  by  the 
gynecologist during surgery and CIN specimens were classified by pathologists according 
to international criteria (Horvat et al., 2008). Informed written consent was obtained from 
all patients in accordance with our institutional guidelines.
CIN2, CIN3 AND NORMAL TISSUE PREPARATION
Each tissue fragment was transferred into a 50 ml centrifuge tube and submerged in 
an ice-bath containing 20 ml of DMEM:F12 transporting medium (with L-glutamine, 15 
mM  HEPES  and  3.151  g/L  glucose;  Lonza,  Milan,  Italy)  with  200  U  ml-1 
Penicillin/Streptomycin  (10,000  U ml-1 penicillin,  10,000  U ml-1 streptomycin;  Lonza, 
Milan, Italy), 0.25 μg ml-1 Amphotericin B (250 μg ml-1; Lonza, Milan, Italy). Under a 
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sterile hood, the transporting medium was removed and the tissue fragments were rinsed 
with 10 ml of sterile PBS 1X (without calcium or magnesium; Lonza, Milan, Italy,) and 
mixed manually 3-4 times. The samples were centrifuged at 400 g at RT for 10 minutes 
and the PBS 1X was discarded. The samples were washed again twice and afterwards the 
PBS 1X was discarded. The tissue fragments were lifted with tweezers and placed in a 10 
cm Petri-dish. Afterwards the tissue fragments were finely cut with a disposable blade. 
During cutting,  it  was followed the direction of the blade edge, and the tissue was not 
dragged  laterally;  to  cut  the  tissue  in  all  directions,  the  Petri-dish  was  turned  around 
periodically. Then, DMEM:F12 medium (with L-glutamine, 15 mM HEPES and 3.151 g/L 
glucose;  Lonza,  Milan,  Italy),  4.5 ml,  was deposited on the Petri-dish and the minced 
specimens were aspirated and transferred into a T25 flask (Corning, Pero, Italy); 500 µl of 
2000 u/ml  Type  II  collagenase  enzyme  solution  (final  concentration  200 u/ml,  Sigma-
Aldrich, Milan, Italy) were added and tissue digestion was performed at 37 °C, with 5% 
CO2, for 24 hrs.  
CIN2, CIN3 AND NORMAL CULTURE SETUP
After  digestion,  cell  suspension was  gently  mixed  to  optimally  disaggregate  all 
tissue fragment residues, and then transferred the into a 10 ml conical tube and centrifuged 
at  400g at  RT,  for  10 minutes.  The supernatant  was discarded and the  cell  pellet  was 
washed twice with 2 ml of PBS 1X. The cell pellet was suspended in 5 ml of DMEM:F12 
complete  medium  (with  L-glutamine,  15  mM  HEPES  and  3.151  g/L  glucose;  Lonza, 
Milan, Italy) with 200 U ml-1 Penicillin/Streptomycin (10,000 U ml-1 penicillin, 10,000 U 
ml-1 streptomycin; Lonza, Milan, Italy), 0.25 μg ml-1 Amphotericin B (250 μg ml -1; Lonza, 
Milan, Italy) and 10% v/v of Fetal Bovine Serum (FBS, Lonza, Milan, Italy) and seeded in 
a T25 flask. Cell cultures were incubated at 37 °C, with 5% CO2. After two days, the cell 
suspension was  transferred  into  a  10  ml  conical  tube  whereas  the  attached  cells  were 
washed twice with 5 ml of PBS 1X; then, 5 ml of fresh DMEM:F12 complete medium was 
added. Cell suspension was centrifuged at 400g at RT for 10 minutes. The cell pellet was 
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washed twice with 2 ml of PBS 1X, then suspended in 5 ml of DMEM:F12 complete  
medium and transferred into a new T25 flask (T2 flask). The cell suspension in the T2 
flask was incubated at 37 °C, with 5% CO2, and leaved to attach for 2 days. After two 
days, the cell suspension of the T2 flask was discarded, the attached cells were washed 
twice with PBS1X and 5 ml of fresh DMEM:F12 complete medium was added.  
CIN2, CIN3 AND NORMAL PRIMARY COLONY EXPANSION
Colonies grown in T1 and T2 flask were analysed with Inverted Nikon TE2000E 
microscope; the larger colonies, and made up of small cells, were selected for expansion. 
DMEM:F12 complete medium was removed and cells were washed twice with 5 ml of 
PBS 1X. The upper surface of the T1 and T2 flasks was opened at the top with a red-hot 
sterile  disposable  blade.  The  flasks  were  carefully  opened  in  order  to  avoid  dropping 
plastic  fragments  onto  the  layer  where  the  cells  were  located.  After  discarding  of  the 
PBS1X, glass cylinders (height 10 mm, external diameter 9 mm, internal diameter 7 mm; 
Elettrofor s.a.s.,  Borsea, Italy)  were used to isolate the single colonies.  Glass cylinders 
were sealed with a silicone rubber and placed around the colonies; after pressing lightly 
down,  so  that  the  cylinders  adhered  well  to  the  bottom of  the  T25  flasks,  cells  were 
detached with 50 µl of 0.05% w/v Trypsin (from bovine pancreas; Sigma-Aldrich, Milan, 
Italy)/0.01% w/v Ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich, Milan, Italy) in 
a PBS 1X solution, at 37°C for 5 minutes. After incubation, most of the cells from different 
colonies were completely detached. However, cells from some colonies were difficult to 
detach and further 3-5 minutes of incubation at 37°C  were needed. Then, cell suspension 
from each colony was recovered and seeded in a well of 6 well culture plate (Corning, 
Pero, Italy) with 2 ml of DMEM:F12 complete medium. Cells were left to attach overnight 
at 37 °C, with 5% CO2. After incubation, the DMEM:F12 complete medium was changed 
with 2 ml  of DMEM:F12 complete  medium/defined Keratinocyte  Serum Free Medium 
(dKSFM, Invitrogen, Monza, Italy) (ratio 1:1) (DMEM:F12/dKSFM) medium. Cells were 
incubated at 37 °C, with 5% CO2 and the DMEM:F12/dKSFM medium was changed every 
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3  days.  Cell  cultures  became  80% confluent  typically  in  4  days  for  CIN2 and  CIN3 
keratinocyte colonies and in 7 days for normal keratinocyte colonies. In order to obtain 
huge amounts of normal and neoplastic keratinocytes, the subconfluent cells were detached 
from each well  with 500 µl  Trypsin/EDTA solution at  37 °C for  5  minutes,  and then 
transferred into a new T25 flasks with 5 ml DMEM:F12/dKSFM medium. Cell cultures 
were incubated at 37 °C, with 5% CO2 and the medium was changed every 3 days. CIN2 
and CIN3 keratinocyte  colonies  grew more  quickly than  normal  keratinocyte  colonies. 
Therefore,  10  days  were  sufficient  to  reach  sub-confluence  for  CIN2  and  CIN3 
keratinocytes and 15 days or more were needed in order for sub-confluence to be reached 
by normal keratinocytes.
IMMUNOFLUORESCENCE ASSAYS
Single CIN3 and normal colonies were isolated with cloning rings, keratinocytes 
were subdivided  onto different  coverslips  and cells  were  grown on microscope  slides. 
Keratinocytes  were fixed by immersing  the slides in  jars filled  with paraformaldehyde 
solution (4% formaldehyde and 0.5% Triton X-100 in PBS 1X) and incubated at 37°C for 
20 min. Keratinocytes were then blocked with 10% goat serum in PBS 1X at 37°C for 1h. 
Subsequently keratinocytes were incubated with different mouse anti-human monoclonal 
antibodies (mabs). To determine the epithelial and cervical markers, immunofluorescence 
staining with K5, K14, K17, and K19 keratins and with p63 (Dako SpA, Milan, Italy) was 
performed, as previously described (Quade et al., 2001; Radu et al., 2002; Martens et al., 
2004; Harper et al., 2007; Tudor et al., 2007). The substitution of primary antibodies with 
PBS 1X served as a negative control. Digital images from a Nikon TE2000E microscope 
were  captured  using  the  ACT-  1  software  for  the  DXM1200F digital  camera  (Nikon, 
Florence,  Italy).  The  percentage  of  cells  expressing  different  keratin  markers  in  the 
colonies was quantified by counting 1,000 cells in four randomly selected fields/colony.
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DNA ISOLATION
DNA was isolated from a small fraction of CIN2, CIN3, and normal specimens and 
from  corresponding  CIN2,  CIN3,  and  normal  keratinocytes  according  to  standard 
procedures, as described (Barrandon and Green, 1987; Bononi et al., 2012; Rotondo et al. 
2012). All  DNA  was  stored  at  -80°C  until  the  time  of  analysis.  Furthermore,  before 
molecular analysis, all DNA was first quantified using the Nanodrop spectrophotometer 
(ND-1000, NanoDrop Technologies, Wilmington, DE USA). To test the suitability of the 
extracted DNA for PCR analysis, isolated DNA was PCR amplified with ß-globin primers 
(Pancaldi et al., 2009).
HPV DETECTION AND GENOTYPING 
Purified DNA from CIN2, CIN3, and normal specimens and from corresponding 
cultured CIN2, CIN3 and normal keratinocytes was amplified for HPV sequences with the 
general  primers  GP5-GP6, which enable detection of HPV -6b, -11,  -16,  -18,  -31,  -33 
genotypes. PCR analysis was carried out with 500 ng human genomic DNA (Barrandon 
and Green, 1987; Bononi et al., 2012; Martini et al., 2004). HPV PCR product sizes were 
139 bp for HPV -6b, -11 and -33 genotypes, 142 bp for HPV -16 and -31 genotypes, and 
145 bp for HPV -18 genotype. PCR products were electrophoretically separated on 2.5% 
agarose gel. To further assess PCR product specificity, a restriction endonuclease analysis 
of  HPV  sequences  was  performed  with  RsaI  digestion  (Barrandon  and  Green,  1987; 
Bononi  et al., 2012). DNA digestion was performed at 37°C for 2 h. The digested DNA 
products were electrophoretically separated on 20% acrylamide gel, and DNA fragment 
size GP5-GP6 amplified  DNA of CIN and HPV PCR (positive  control)  products were 
compared. 
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RNA ISOLATION
Total RNA was extracted from CIN2, CIN3, and normal keratinocytes by use of a 
RNAzol kit (Life Technologies, Milan, Italy), according to the manufacturer’s instructions. 
All RNA was stored at -80°C until the time of analysis.  Furthermore,  before molecular 
analysis, all RNA was first quantified using the Nanodrop spectrophotometer (ND-1000, 
NanoDrop Technologies, Wilmington, DE USA).
WHOLE  HUMAN  GENOME  EXPRESSION  DETECTION  BY 
OLIGO MICROARRAY
RNA from CIN2, CIN3 and normal keratinocytes was hybridized on Agilent whole 
human genome oligo microarray (Agilent Technologies, Palo Alto, CA). This microarray 
consists of 60-mer DNA probes which have been synthesized in situ and represent 41,000 
unique human transcripts.  One-colour  gene expression was performed according to the 
manufacturer’s  procedure.  Briefly,  RNA  quality  was  assessed  with  Agilent  2100 
Bioanalyzer (Agilent Technologies). Low quality RNA (RNA integrity number below 7) 
was 6 excluded from microarray analyses. Labelled cRNA was synthesized from 500 ng of 
total RNA using the Low RNA Input Linear Amplification Kit (Agilent Technologies) in 
the presence of cyanine 3-CTP (Perkin-Elmer Life Sciences, Boston, MA). Hybridizations 
were performed at 65°C for 17 hours in a rotating oven. Images at 5 μm resolution were 
generated  by  the  Agilent  scanner,  and  Feature  Extraction  10.5  software  (Agilent 
Technologies) was used to obtain the microarray raw data. 
MICROARRAY DATA ANALYSIS
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Microarray raw data were analyzed by use of GeneSpring GX 10 software (Agilent 
Technologies). Data transformation was applied to set all the negative raw values at 1.0, 
followed by normalization at the 75th percentile. A filter on low gene expression was used 
to keep only the probes expressed in at least one sample (flagged as Marginal or Present). 
Then,  samples  were  grouped  according  to  their  differentiation  status  and  compared. 
Differentially expressed genes were selected as having a 1.5-fold expression difference 
between  their  geometrical  mean  in  two or  more  groups  of  interest,  and  a  statistically 
significant p-value (<0.05) according to ANOVA (analysis of variance) and Benjamini and 
Hoechberg correction for reduction of false-positive values. Differentially expressed genes 
were employed for sample cluster analysis by use of the Pearson correlation as a measure 
of  similarity.  The  microarray  raw  data  have  been  deposited  at  ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-2019. 
REVERSE  TRANSCRIPTION  QUANTITATIVE  REAL-TIME 
PCR (RT-QPCR)
The  differential  expression  of  selected  genes  in  CIN2,  CIN3  and  normal 
keratinocytes  was  validated  by  Reverse  Transcription  quantitative  real-time  PCR (RT-
qPCR). Briefly, 300 ng total RNA was reverse transcribed with a random hexamer primer 
using High Capacity RNA-to-cDNA Kit (Roche Applied Science, Milan, Italy), according 
to  the manufacturer’s instructions. qPCR monitoring was performed with the ABI 7500 
Fast  Real  Time  PCR system (Roche  Applied  Science)  and  Power  SYBR Green  PCR 
Master Mix (Roche Applied Science). The following eight genes were investigated: RARB 
(Bohlken et al., 2009), IRF6 (Restivo et al., 2011), TIMP3 (Bernot et al., 2010), APOC1 
(Oue et al., 2004), MSX1 (Chetcuti et al., 2011), PHGDH (Liu et al., 2013), C-JUN (De-
Castro  et  al., 2004)  and  p63  (Yalcin-Ozuysal1  et  al., 2010).  The  glyceraldehyde-3-
phosphate dehydrogenase gene (GAPDH) was used as an internal control (Chetcuti et al., 
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2011). Each assay was performed in triplicate. Data analysis was performed with the 2-
⊿⊿
Ct 
method. 
IMMUNOHISTOCHEMICAL (IHC) ANALYSIS
Immunohistochemical  (IHC)  analysis  was  performed  on  paraffin-embedded 
specimens from 30 patients with CIN lesions (10 CIN1, 10 CIN2 and 10 CIN3), from 4 
with invasive squamous cell cervical cancer, and from 10 with normal cervical tissue. The 
IHC staining  was  performed  by use  of  the  Multimeric  Detection  Kit  (Universal  DAB 
Detection  Kit  Ultraview,  Roche  Tissue  Diagnostics  (CH),  on  a  BenchMark  XT 
immunostainer (Roche T.D.). Paraffin-embedded tissue sections (4 μm thick) were stained 
with mouse monoclonal  3PGDH antibody sc-100317 (Santa Cruz Biotechnology,  Santa 
Cruz, CA) (dilution, 1:50). HeLa cells, processed as tissues, ie. pelleted, fixed and paraffin-
embedded, were used as positive controls, as recommended by the manufacturer. Staining 
intensity and the distribution of staining were assessed by two pathologists. Staining was 
graded as negative (no staining) and as weak, moderate, or strong intensity.
SODIUM BISULFITE TREATMENT OF DNA
DNA from CIN2, CIN3 and normal keratinocytes was treated with sodium bisulfite 
using the Epitect Bisulfite kit (Qiagen, Milan, Italy) as previously described (Rotondo   et  
al  ., 2013). Sodium bisulfite treatment induces the conversion of unmethylated cytosines of 
DNA  to  uracil,  while  leaving  the  5-methylcytosines  unchanged.  Samples  were  then 
purified using DNA purification columns (Epitect Bisulfite kit, Qiagen).
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RARB METHYLATION PCR PRIMERS DESIGN
RARB methylation PCR primers were designed using the MethPrimer informatics 
software  (Li  and  Dahiya,  2002).  Briefly,  MethPrimer is  a  software  for  methylation 
designing PCR primers for methylation investigation. In a first step, this software is able to 
search for all CpGs in a limit input sequence of 5 Mbp.  In a second step the software can 
design  primers  within  the  imput  sequence  through  general  parameters  changes,  like 
product Size, primer Tm, etc. (Li and Dahiya, 2002).
BISULFITE  TREATED  DNA  PCR  OF  RARB  AND  IRF6 
PROMOTER REGION
The methylation assay was performed at the promoter region of RARB and IRF6 
genes. 150 ng of sodium bisulfite-treated CIN2, CIN3 and normal keratinocytes DNA was 
amplified at the RARB and IRF6 (Botti  et al., 2011) loci by Bisulfite treated DNA PCR. 
The RARB promoter region studied contained 14 CpG islands whereas the IRF6 promoter 
region studied contained 25 CpGs.
DNA CLONING AND SEQUENCING
Amplified products were purified with the QIAquick PCR Purification Kit (Qiagen) 
and then cloned with the TOPO TA cloning kit (Invitrogen), using the Turbo Competent E. 
coli bacteria strain (EuroClone) and the pCR 2.1-TOPO vector (Invitrogen), according to 
manufacturer’s  instructions.  Selection  of  bacterial  clones  containing  the  fragment  of 
interest  was performed using selective LB growth medium with ampicillin (100 μg/ml, 
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Sigma-Aldrich). For each DNA sample, 10 positive clones were selected for sequencing 
analysis.  Single clones  were sequenced using automated  ABI Prism Genetic  (Analyzer 
Applied Biosystems).
STATISTICAL ANALYSIS
The observed RARB and IRF6 epigenotype  frequencies  (i.e.  methylated  CpGs) 
were compared between groups using the chi-square trend test with Yates' correction. All 
statistical  analyses  were  carried  out  using  Graph Pad  Prism version  5.0  for  Windows 
(Graph Pad, La Jolla, CA, USA). P-values < 0.05 were considered statistically significant.
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RESULTS
HPV-DNA ANALYSIS OF CIN2, CIN3 AND NORMAL 
SPECIMENS AND KERATINOCYTES
In a first step of our experiments, high-risk HPV16  presence in CIN2 and CIN3 
specimen was investigated. To this purpose, CIN and normal specimens, were screened by 
PCR for HPV DNA sequences.  All  normal  samples  were negative for HPV sequences 
(Figure  5,  A). CIN2  and  CIN3  keratinocyte  specimens  tested  positive  for  HPV16 
sequences were selected for the present study (Figure 5, A, B). The DNA fragment sizes 
for HPV types are shown in the table 3. Subsequently, in a second step, in order to confirm 
HPV detection and genotyping, the same DNA analysis was performed in CIN2 and CIN3 
keratinocytes. Previous CIN specimens data were confirmed. 
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HPV type  Total length (bp)    Length of RsaI restriction
fragments (bp)
30
HPV-6 139 42
67
30
HPV-11 139 109
30
HPV-16 142 42
70
30
HPV-18 145 38
77
30
HPV-31 142 112
30
HPV-33 139 39
70
Table  3.  DNA fragment  sizes  for  HPV types  spanned  by  GP5/GP6  primer  set  and  
fragment lengths generated by RsaI restriction enzyme digestion.
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Figure 5. HPV PCR and HPV genotyping. A: the agarose gel shows HPV PCR results  
obtained  from  the  CIN2,  CIN3,  and  normal  keratinocyte  DNA  specimens.  HPV PCR  
products are only visible in the CIN2 and CIN3 samples  (lanes 1 and 2). MW: molecular  
weight markers are 100 bp  (left); HPV-16: PCR positive control; C-: negative control of  
the PCR reaction without DNA template. B: polyacrylamide gel shows HPV genotyping of  
HPV PCR products  from the  CIN2 and CIN3 specimens.  The  CIN2  (lanes  1 and 2)  
specimens and CIN3  (lanes  1 and 2) are positive  for HPV-16. Fragment  lengths  are  
reported in table 3. M.W.: molecular weight markers are 100 bp  (M.W. I) and 50 bp  
(M.W. II)  ladder. HPV-6b, -11, -16, -18, -31 and -33: HPV controls.
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CIN2, CIN3 AND NORMAL KERATINOCYTES CULTURES 
SETUP
The protocol  is  developed in  two main  steps:  (i)  CIN and normal  keratinocyte 
primary culture preparation, (ii) CIN and normal keratinocyte primary colony expansion. 
CIN tissue fragments are obtained from CIN patients during the excision of a cone-shaped 
portion of preneoplastic tissue under colposcopic examination. Since excided CIN tissue 
specimens include surrounding normal tissue, a small fragment of normal cervical tissue 
can be taken from each corresponding CIN tissue specimen. The isolation of all the total 
cells from the small CIN and normal cervical tissue relies on a collagenase digestion step. 
Then, separated cells are washed, counted and seeded in T25 flasks (T1) with DMEM:F12 
medium  and  10%  foetal  bovine  serum  (FBS).  Approximately,  1x104-2x105 cells  are 
isolated from each CIN and normal tissue fragment. After seeding, cells are left to attach 
for 48 h; then, any unattached cell suspension is recovered, washed and reseeded for a 
further  48  h  in  new  T25  flasks  (T2).  This  re-seeding  procedure  allows  keratinocytes 
endowed with slow attachment capability to be rescued later and therefore enables total 
primary  colony  numbers  per  specimen  to  be  increased.  Representative  primary 
keratinocyte colonies from a CIN3 specimen are shown in figure 6. CIN2 and CIN3 tissues 
give the best primary cultures, producing approximately 200-400 colonies/tissue. Normal 
cervical  tissues  give  rise  to  a  lower  number  of  colonies,  ranging  from  50  to  80 
colonies/tissue.  Frequently,  T2 flasks develop many more colonies  than T1 flasks.  The 
duration of the procedure is 3-4 weeks; however, CIN2 and CIN3 keratinocyte colonies 
can be well visible in 2-3 weeks. Keratinocytes and fibroblasts are well distinguishable in 
primary  cell  cultures.  Indeed,  keratinocytes  grow forming  colonies  whereas  fibroblasts 
proliferate sparsely (Figure 6, A), or in disordered cell clusters or in parallel bundle groups 
(Figure 6, C). Keratinocyte colonies grow surrounded by fibroblasts (Figure 6, B, C) or 
isolated (Figure 6, A). CIN2, CIN3 and normal primary cultures develop three different 
types  of  colonies,  which  are  classified  on  their  cell  content  and  morphology:  type  I 
colonies  contain  cells  which  are  irregularly  sized,  flattened  or  spindle-shaped  and  are 
loosely spaced (endowed with a  low proliferation  rate)  (Figure 6,  A);  type  II  colonies 
consist of small, compact and uniform sized cells (endowed with a high proliferation rate) 
(Figure 6, B); type III colonies contain smaller, more compact and more uniform size cells  
than those of type II (endowed with a very high proliferative rate) (Figure 6, C). CIN2 and 
CIN3 primary cultures develop approximately 70% type II/type III colonies and 30% type 
I colonies, whereas normal primary cultures 50% type II and 50% type I colonies. Type II 
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and  III  colonies  can  be  expanded  efficiently  since  they  are  endowed  with  a  high 
proliferative capability. 
Figure 6.  Keratinocyte primary colonies of a CIN3 culture. (A) A type I colony. Arrow 
indicates a fibroblast; (B) a type II colony. Arrow indicates a fibroblast; (C) a type III  
colony. Arrows indicate parallel bundle groups of fibroblasts.
IMMUNOFLUORESCENCE CHARACTERIZATION
Immunofluorescence  characterization  on  round  coverslip  was  assessed  in  CIN3 
(Figure 7) and normal primary and expanded colonies. All CIN3 and normal colonies were 
analyzed for K14, K17, and K19  keratins and p63 expression. The CIN3 primary colonies 
react strongly for K14 (Figure 7, A) , K17 (Figure 7, B) , K19 (Figure 7, C) as well as for 
p63 in all  cells  (Figure 7,  D).  In some normal primary colonies  K14 and K19 stained 
strongly in all  cells whereas K19 reacted with a moderate signal in only 50% of cells. 
Furthermore, staining for p63 was negative. The CIN3 and normal colonies expanded with 
the new mixture DMEM-F12/dKSFM (1:1 ratio) cell culture medium stained strongly for 
K14, K17, K19, and p63 (Figure 7, A-D, insert), and for K14 and K19. Expanded colonies 
maintain the same staminal and epithelial markers as the primary colonies from which they 
originated as shown in figure 7.
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Figure 7.  Immunofluorescence staining.  Panels  A-D: immunofluorescence staining of  
type III colonies from a CIN3 culture. Cells react strongly to K14 (A), K17 (B) and K19 
(C) keratins (markers of cervical keratinocytes; cytoplasmic signal) and p63 (D) (marker  
of cervical staminal keratinocytes; nuclear signal). Keratinocytes from type III colonies  
expanded in the new medium mixture maintain high expression of K14 (panel A, inset),  
K17 (panel B, inset), K19 (panel C, inset) and p63 (panel D, inset).
IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES 
IN CIN KERATINOCYTES
To identify genes associated with progression of CIN lesions, it was examined the 
gene expression profiles in two CIN2, two CIN3, and two normal keratinocytes obtained 
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by tissue cultures from four CIN patients.  The genes modulated during the progression 
from  normal  to  CIN2  keratinocytes  and  from  CIN2  to  CIN3  keratinocytes  were 
investigated. One hundred and thirteen genes were significantly down-regulated in CIN2 
keratinocytes compared with normal keratinocytes, and 211 genes were down-regulated in 
CIN3  compared  with  CIN2  keratinocytes  (P<0.05  and  fold-change  >2).  A  consistent 
down-regulation  from  normal  to  CIN2  keratinocytes,  and  from  CIN2  to  CIN3 
keratinocytes, was observed for the following 23 genes: INHBB, SLC38A11, IRX2, RARB, 
TIMP3, ALDH1A3,  ABCB4, EFNB2,  C6orf168, ATP2A3,  FMO3, FMO4,  NCAM2,  TLR2, 
IRF6, SYNM, HIST1H2AC, FRMPD4, LIMS3, C1orf96, FBXO32, HIST2H2BE and IFIT2 
(Table 4 and Figure 8, A). One hundred seventy-five genes were significantly up-regulated 
in CIN2 keratinocytes compared with normal keratinocytes, and 94 were up-regulated in 
CIN3 keratinocytes compared with CIN2 keratinocytes (P<0.05 and fold-change >2). A 
consistent  up-regulation  from normal  to  CIN2  keratinocytes  and  from  CIN2  to  CIN3 
keratinocytes  was  detected  for  14  genes:  FOXD2,  SCARA5,  OLFM1,  LPAR1,  SFRP2, 
MSX1,  APOC1,  KLF2,  TAGLN,  SFXN2,  TMEM54,  PHGDH,  SPOCD1,  and  ARNTL2 
(Table 4 and Figure 8, B). Genes consistently up- or down-regulated during transition from 
CIN2 to CIN3 were used to perform a hierarchical clustering analysis (Figure 9). Normal, 
CIN2 and CIN3 keratinocytes grouped in three different clusters and showed a distinct 
gene expression pattern (Figure 9).
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Figure 8. Genes differentially expressed revealed by microarray analysis..A: Intersection 
between  the  113  genes  down-regulated   (p<0.05  and  FC<0.5)  in  CIN2  keratinocytes  
(CIN2) compared with normal keratinocytes and the 221 genes down-regulated  (p<0.05  
and FC<0.5) in CIN3 keratinocytes  (CIN3) compared with CIN2 keratinocytes   (CIN2).  
Twenty-three genes are in common. B: Intersection between the 175 genes up-regulated  
(p<0.05 and FC>2) in CIN2 keratinocytes  (CIN2) compared with normal keratinocytes,  
and  the  94  genes  up-regulated   (p<0.05  and  FC>2)  in  CIN3  keratinocytes   (CIN3)  
compared with CIN2 keratinocytes  (CIN2). Fourteen genes are in common. 
_________________________________________________________________________
Gene symbol Gene Bank acc. no. Function
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23 down regulated genes
INHBB NM_002193 Immune response
SLC38A11 NM_173512 Amino acid transport
IRX2 NM_033267 DNA binding
RARB NM_000965 DNA binding
TIMP3 NM_000362 Proteolysis
ALDH1A3 NM_000693 Apoptotic process
ABCB4 NM_018850 Metabolic process
EFNB2 NM_004093 Cell-cell signaling
C6orf168 NM_032511 Unknown
ATP2A3 NM_174953 Nucleotide binding
FMO4 NM_002022 Metabolic process
NCAM2  NM_004540.3 Cell-cell adhesion 
FMO3 NM_001002294 Metabolic process
TLR2 NM_003264 Immune response
IRF6 NM_006147 Transcription factor 
SYNM NM_145728 Cytoskeleton constituent
HIST1H2AC NM_003512.3 DNA binding
FRMPD4 NM_014728                         Protein binding 
LIMS3 NM_033514 Zinc ion binding
C1orf96 NM_145257 Embryonic development 
FBXO32 NM_058229 Protein ubiquitination
HIST2H2BE NM_003528 DNA binding
IFIT2 NM_001547 Immune response
14 up regulated genes
FOXD2 NM_004474 DNA binding
SCARA5 NM_173833 Transmembrane transport
OLFM1 NM_006334 Cell junction
LPAR1 NM_012152 Signal transduction
SFRP2 NM_003013 Cell-cell signaling 
MSX1 NM_002448 DNA binding
APOC1 NM_001645 Metabolic process
KLF2 NM_016270 DNA binding 
TAGLN NM_001001522 Organ development
SFXN2 NM_178858 Transmembrane transport
TMEM54 NM_033504 Unknown
PHGDH NM_006623.3 Metabolic process
SPOCD1 NM_144569.5 Transcription
ARNTL2 NM_001248002.1 DNA binding
_________________________________________________________________________
Table 4. Consistently down-modulated and up-modulated genes identified in CIN2 and  
CIN3 keratinocytes.
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Figure  9.  Cluster  analysis  of  normal  keratinocytes,  CIN2  and  CIN3  keratinocytes  
performed  in  accordance  to  the  expression  of  commonly  modulated  genes,  both  
annotated  (with gene symbol) and not annotated  (N/A). Genes are in rows, samples in  
columns. The colors of the genes represented on the heat map correspond to the values  
normalized  on  miRNA  average  expression  across  all  samples   (see  color  bar);  up-
regulated miRNAs are in red, down-regulated miRNAs in green.
VALIDATION OF MICRARRAY DATA BY RT-QPCR
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To confirm the gene expression data identified by microarray analysis, total RNA 
isolated  from  the  two  CIN2,  two  CIN3  and  two  normal  keratinocyte  specimens  was 
subjected  to  QRT-PCR analysis.  Three  consistently  down-regulated  genes  from the 23 
candidate genes (RARB, IRF6, and TIMP3) and three consistently up-regulated genes from 
the  14  candidate  genes  (APOC1,  MSX1,  and  PHGDH)  were  chosen.  Representative 
amplification plot is showed in figure.  In accordance with microarray analysis, the mRNA 
expression level  of  RARB,  IRF6,  and  TIMP3  was significantly  decreased  from that  of 
normal and CIN2 keratinocytes and from that of CIN2 and CIN3 keratinocytes (Figure 11). 
Specifically, the RARB gene was significantly down-regulated by 8.9-fold and 29.2-fold in 
CIN2 and CIN3 keratinocytes, respectively, compared to normal keratinocytes (Figure 11). 
As for RARB, IRF6 also resulted down-expressed: 3.6-fold and 7.2-fold in CIN2 and CIN3 
keratinocytes,  respectively,  compared  to  normal  keratinocytes  (Figure  11).  Similarly, 
TIMP3 gene resulted significantly down-regulated by 5.6-fold and 13.7-fold in CIN2 and 
CIN3  keratinocytes,  respectively,  compared  to  normal  keratinocytes  (Figure  11). 
Differences in RARB, IRF6 and TIMP3 mRNA expression levels between CIN2 and CIN3 
keratinocytes were statistically significant (p<0.0001). 
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 Figure 10. Reappresentative real-time quantitative RT-PCR amplification plot  of:  (A)  
RARB,  IRF6,  TIMP3,  and  the  housekeeping  gene  GAPDH  and  (B)  APOC1,  MSX1,  
PHGDH and GAPDH.
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Figure 11. Differential expression of RARB, IRF6, TIMP3 genes measured with real-
time quantitative RT-PCR in specimens from CIN2 and CIN3 keratinocytes.  Relative  
expression was calculated by use of  the ∆∆Ct method. Data are expressed as a relative  
fold  change   (2-∆∆Ct)  over  the  value  of  normal  specimens.  GAPDH gene  was  used  as  
internal control. *P <0.0001 versus CIN2.
In  contrast,  the  expression  levels  of  APOC1,  MSX1  and  PHGDH  mRNA 
continuously increased both from normal to CIN2 keratinocytes and from CIN2 to CIN3 
keratinocytes (Figure 12). Specifically, the APOC1 gene was significantly up-regulated by 
7.4-fold and 10-fold in CIN2 and CIN3 keratinocytes, respectively, compared to normal 
keratinocytes (Figure 12).  Similarly,  up-expression of PHGDH was also detected. This 
gene resulted up-regulated  by 5.6-fold and 10.6-fold in  CIN2 and CIN3 keratinocytes, 
respectively,  compared  to  normal  keratinocytes  (Figure  12).  MSX1  gene  resulted 
significantly  up-regulated  by  3.5-fold  and  14-fold  in  CIN2  and  CIN3  keratinocytes, 
respectively,  compared  to  normal  keratinocytes  (Figure  12).  Differences  in  APOC1, 
PHGDH and MSX1 mRNA expression levels between CIN2 and CIN3 keratinocytes were 
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statistically significant (p<0.0001).These findings indicate that the data obtained from the 
microarray analysis are reliable and that these 37 genes may be significant contributors in 
the progression of high-grade HPV16 CIN lesions. 
Figure12. Differential  expression of APOC1, MSX1, PHGDH  genes measured with  
real-time  quantitative  RT-PCR  in  specimens  from  CIN2  and  CIN3  keratinocytes.  
Relative expression was calculated by use of  the ∆∆Ct method. Data are expressed as a  
relative fold change  (2-∆∆Ct) over the value of normal specimens.  GAPDH gene was used  
as internal control. *P <0.0001 versus CIN2.
IHC ANALYSES
The IHC staining of CIN and normal  cervical tissue samples validated PHGDH 
protein expression. PHGDH staining was cytoplasmatic. As shown in figure 13, in normal 
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tissues, PHGDH was weakly expressed and only in the proliferative compartment of the 
epithelium.  In cervical  cancer  tissue,  strong staining was present  in  all  tissue sections. 
Strong staining of dysplastic cells was present in 9/10 CIN3, 7/10 CIN2 and 10/10 CIN1 
lesions; one out of ten CIN3 and 3/10 CIN2 lesions showed moderate staining of dysplastic 
cells (data not shown). PHGDH staining extended to the superficial layers in CIN3 cases, 
to the mid layer in CIN2 lesions, and to the lower third of the epithelium in CIN1 lesions, 
corresponding to the extension of the dysplastic proliferative compartment in the different 
types of lesions. Nondysplastic cells in CIN cases were stained only weakly or not at all. 
The specificity of IHC staining for PHGDH protein in CINs and cervical cancers indicates 
that PHGDH is likely associated with tumorigenesis.
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Figure 13.  Immunohistochemical  analysis  of  PHGDH in  CIN,  cervical  cancer,  and  
normal tissues. Immunohistochemical  analysis  with  anti-PHGDH polyclonal  antibody  
confirmed the elevated expression of this protein in dysplastic cells from CIN1  (B), CIN2  
(C), CIN3  (D) lesions, in tumor cells from invasive carcinoma  (E), and in HeLa cells  (F)  
compared with the  expression in proliferative cells from normal cervical tissue  (A).
RARB, C-JUN, IRF6 AND P63 GENE EXPRESSION ANALYSIS
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In order to explore the expression trend of RARB, c-Jun, IRF6 and p63 mRNAs, 10 
CIN2, 10 CIN3, positive for HPV16, and 10 normal keratinocyte specimens was subjected 
to  QRT-PCR  analysis. As  reported  previously  in  this  work  (page 47),  the  mRNA 
expression level of RARB and IRF6, resulted significantly decreased from that of normal 
and CIN2 keratinocytes  and from that of CIN2 and CIN3 keratinocytes  (Figure 14, B) 
(P<0.0001).  Specifically,   RARB was  significantly  down-regulated  by 9.3-fold  and by 
35.8-fold in CIN2 and CIN3 keratinocytes, respectively, compared to normal keratinocytes 
(figure  3,  B). Differences  in  RARB  expression  levels  between  CIN2  and  CIN3 
keratinocytes were statistically significant (p>0.0001).  In contrast,  the amount of c-Jun 
mRNA was found to correlate with the degree of pre-neoplastic CIN lesion: the lowest in 
CIN2  (4.3-fold   up-regulated  compared  to  normal)  and  the  highest  in  CIN3  (22  up-
regulated compared to normal) (Figure 14, B) (P<0.0001). Indeed, differences in c-Jun 
expression  levels  between  CIN2  and  CIN3  keratinocytes  were  statistically  significant 
(p>0.0001). As for RARB, IRF6 mRNA was Similarly down-regulated by 2.9-fold and 
6.7-fold in CIN2 and CIN3 group, respectively, compared to normal keratinocytes (figure 
15, B). Contrariwise,  p63 was significantly high expressed by 3.6-fold and by 15-fold in 
CIN2 and CIN3 keratinocytes, respectively, compared to normal keratinocytes (figure 15, 
B). Differences in IRF6 and p63 expression levels between CIN2 and CIN3 keratinocytes 
were statistically significant (p>0.0001).
RARB AND IRF6 PROMOTER METHYLATION ANALYSIS
The methylation status of the RARB and IRF6 loci was investigated by sequencing 
analysis of the cloned PCR products. A total of 120 clones were investigated for the DNA 
methylation status of RARB and IRF6 loci in bisulfite-treated DNA samples from CIN 
keratinocytes. RARB and IRF6 clones derived from two HPV16-CIN2, two HPV16-CIN3 
and two normal RARB and IRF6 PCR products (10 from each sample) were randomly 
selected for DNA sequencing. The overall distribution of the different clones within CIN 
keratinocytes, within CIN2 and normal as well as within CIN3 and normal keratinocytes 
was evaluated. Only RARB or IRF6 hypermethylated clones i.e., clones showing 50% (or 
more than 50%) methylated CpG islands, were taken into account in this analysis. RARB 
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hypermethylation was detected in 9/11 (45%) of the clones from the CIN2 keratinocytes 
and  in  16/20  (80%)  of  the  clones  from  the  CIN3  keratinocytes.  Whereas,  in  normal 
keratinocytes,  RARB  hypermethylation  was  never  detected.  The  difference  in  RARB 
hypermethylation  between  CIN2  and  CIN3  keratinocytes  was  statistically  significant 
(P<0.05,  Figure  14,  A,  Figure  15)  as  well  as  difference  between  CIN2  and  normal 
keratinocytes  (p<0.01,  Figure  14,  A,  Figure  15)  and  CIN3  and  normal  keratinocytes 
(p<0.0001, Figure 14, A, Figure 15). IRF6 hypermethylation was detected in 6/20 (40%) of 
the clones from the CIN2 keratinocytes and in 11/20 (55%) of the clones from the CIN3 
keratinocytes.  Whereas,  as  for  RARB,  in  normal  keratinocytes,  it  was  never  detected 
(Figure 14, A, Figure 15). No significant differences in IRF6 hypermethylation frequencies 
were evaluated between CIN2 and CIN3 keratinocytes (p>0.05, Figure 16, A, Figure 17). 
However, the difference between CIN2 and normal keratinocytes (p<0.05, Figure 16, A, 
Figure  17)  as  well  as  CIN3  and  normal  keratinocytes  (p<0.0001,  fig.  3.  A)  resulted 
statistically significant. 
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Figure 14.  RARB  promoter  methylation  pattern  and RARB  and  c-Jun  differential  
expression. (A)  Bisulfite-PCR sequencing  for  (A)  RARB gene  promoter  region in  one  
representative Normal, CIN2 and CIN3 cultured keratinocytes. Filled-in and clear circles  
represent methylated and unmethylated CpG islands, respectively. The CpG islands within  
the RARB locus is numbered on the upper side of the circles. Each line represents one  
clone.  For the analysis, were considered ten clones per sample. (B) RARB and  c-Jun  
differential  expression  measured  by  real-time  quantitative  RT-PCR in  specimens  from  
CIN2 and CIN3 keratinocytes. Relative expression was calculated using the ∆∆Ct method.  
Data are expressed as a relative fold change (2-∆∆Ct) over the value of normal specimens.  
*P <0.0001 versus CIN2. 
53
Figure 15.  Frequency of  RARB hypermethylation clones in normal, CIN2 and CIN3  
keratinocytes. Only clones showing 50% or more than 50% methylated CpG islands were  
taken into account in this analysis
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Figure 16.  IRF6  promoter  methylation  pattern  and IRF6  and  p63  differential  
expression. (A)  Bisulfite-PCR  sequencing  for  (A)  IRF6  gene  promoter  region  in  one  
representative Normal, CIN2 and CIN3 cultured keratinocytes. Filled-in and clear circles  
represent methylated and unmethylated CpG islands, respectively. The CpG islands within  
the IRF6 locus is numbered on the upper side of the circles.  Each line represents one  
clone.  For  the  analysis,  were  considered  ten  clones  per  sample. (B)  IRF6  and  p63 
differential  expression  measured  by  real-time  quantitative  RT-PCR in  specimens  from  
CIN2 and CIN3 keratinocytes. Relative expression was calculated using the ∆∆Ct method.  
Data are expressed as a relative fold change (2-∆∆Ct) over the value of normal specimens.  
*P <0.0001 versus CIN2. 
Figure 17.  Frequency of  IRF6 hypermethylation clones in normal, CIN2 and CIN3  
keratinocytes. Only clones showing 50% or more than 50% methylated CpG islands were  
taken into account in this analysis
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DISCUSSION 
CIN AND NORMAL KERATINOCYTES CULTURES
Recognition of the role of Human Papilloma Virus (HPV) as the etiologic agent in 
cervical  cancer  has  focused  attention  on  the  mechanisms  inducing  transformation  in 
cervical keratinocytes (Zur Hausen, 1996; Togtema et al., 2012; Lindel et al., 2012; Herfs 
et  al.,  2012;  Kaczkowski  et  al., 2012;  Tan  et  al.,  2012;  Malinowski,  2005).  Due  to 
difficulties in propagating HPV in culture (Angeletti, 2005; Pyeon et al., 2005. McLaughli 
and Meyers  ,2005).  Molecular  characterization  of  naturally  infected-HPV keratinocytes 
derived from cervical preneoplastic lesions is a promising cell study model for elucidating 
HPV-induced cancerogenesis in the human cervix. The HPV transformation process occurs 
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in  multiphase  steps  which  are  clinically  diagnosed as  cervical  intraepithelial  neoplasia 
(CIN) -1, 2 and 3 (Mitchell  et al., 1996; Schiffman et al., 2007). Two published methods 
have been previously described for culturing keratinocytes derived from CIN1-3 lesions as 
well as from normal cervical tissues  (Freshney and Freshney, 2002; Green, et al., 1977). 
With one method, keratinocytes are grown in co-culture with mouse fibroblasts which are 
inactivated  with  mitomycin  C or  gamma rays (feeder  cells)  and  submerged  in  culture 
medium  (Freshney and Freshney, 2002). The alternative approach regards the employment 
of defined keratinocyte-specific medium which allows keratinocyte expansion without the 
use of fibroblast feeder layers (Green, et al., 1977). However, there are some limitations to 
culturing CIN and normal cervical keratinocytes by these methods. Firstly, a large number 
of pure CIN or normal keratinocytes, i.e. free from cervical fibroblasts, is needed to start 
primary  cultures.  Whilst  an  adequate  number  of  normal  cervical  keratinocytes  can  be 
isolated from cervical epithelium obtained from hysterectomy specimens (Narisawa-Saito 
and Kiyono,  2007)   CIN tissue  specimens  are  usually  very  small  and do not  allow a 
sufficient number of pure keratinocytes to be isolated for culturing purposes. Secondly, the 
procedure for isolating pure keratinocytes requires several steps, which increase the risk of 
cell culture contamination.
Therefore, the development of a rapid and easy method of enabling cultures of CIN 
and normal cervical keratinocytes to be grown using small amounts of starting material 
was considered useful. The search for a new culturing method began with the observation 
that seeding the total number of cells isolated from a complete enzymatic digestion of CIN 
or  normal  cervical  tissues,  a  typical  range  of  morphologically  differing  keratinocyte 
colonies,  based  on  their  cell   content  and  general  morphology,  could  be  obtained. 
Additional studies from our laboratories demonstrated that by sufficiently diluting cells 
during  primary  propagation,  CIN  and  normal  keratinocyte  colonies  develop  clonally. 
Furthermore, different CIN and normal keratinocyte primary clonal colonies consisted of 
small, compact and uniform size cells, indicating that cultured keratinocytes were endowed 
with high proliferative potential (Barrandon and Green, 1985, 1987). On the basis of these 
observations, a cell culturing method which employs small CIN and normal cervical tissue 
fragments  to  derive  primary  CIN  and  normal  keratinocyte  clonal  colonies  capable  of 
further expansion was set up. 
Although two different methods for CIN and normal cervical keratinocyte cultures 
have been reported, a very few studies regarding cellular and molecular characterization of 
naturally infected HPV CIN1-3 or normal cervical keratinocytes, have been published to 
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date. These studies have been carried out in W12 and CIN 612 cells, two naturally HPV16-
infected keratinocyte lines derived from CIN1 lesions (Rader  et al., 1990; Bedell  et al., 
1991; Gray et al., 2010; Dall  et al., 2008). The reason for lacking of researchers on CIN 
keratinocytes is that previous culturing methods work well when large pieces of CIN or 
normal cervical tissues are employed, but these are rarely obtained from gynaecological 
surgery.  By  using  murine  fibroblasts  as  feeder  layers,  the  number  of  CIN  or  normal 
keratinocytes seeded must  maintain a  1:2 density ratio  with the murine fibroblasts  co-
cultured in vitro (for an example, 1x104/cm2:2x104/cm2) (Rader et al., 1990; Freshney and 
Freshney, 2002). Alternatively, the number of CIN or normal keratinocytes seeded must be 
at a density of 2x105/cm2  (Barrandon and Green, 1987),  using the specific keratinocyte 
defined  medium  without  murine  fibroblasts.  The  main  procedure  for  isolating  pure 
keratinocytes includes dermal sheet elimination, by dispase digestion or tissue scraping, 
and two consecutive digestions of cervical epithelial tissues by trypsin-EDTA. Due to the 
small size of CIN tissues, CIN keratinocytes are also isolated following migration from 
micro-dissected CIN explants. However, the major problem in this latter procedure is that 
CIN keratinocytes are rescued at a low number and are frequently highly contaminated by 
cervical fibroblasts, which do not allow primary cultures to be started successfully.
The protocol described in this work is very simple compared to previous CIN and 
normal tissue culture methods. CIN and normal cervical keratinocyte primary colonies can 
be obtained in a single technical passage, i.e. after tissue digestion. Consequently, the time 
required  is  highly  reduced.  Moreover,  our  culture  method  enables  CIN  and  normal 
keratinocytes to be grown at a clonal rate by seeding the cells at a high dilution during 
primary  propagation.  This  is  an  important  aspect  since  CIN  lesions  are  clonally 
heterogeneous,  due  to  the  multiphase  steps  of  HPV-induced  carcinogenesis;  therefore, 
clonal  CIN  keratinocyte  cultures  allow  different  CIN  keratinocyte  clones  of  the 
preneoplastic  specimen  to  be  faithfully  reproduced  in  vitro.  Finally,  primary  CIN and 
normal  keratinocyte  clones can be expanded at  highly proliferative rates  over different 
passages with no sign of differentiation. When taken altogether, these results may provide 
important  findings  on  the  mechanisms  induced  by  HPV  during  onset/progression  of 
cervical neoplasia.  CIN2, CIN3 and normal cervical primary culture preparation provides 
the onset of a series of problems due mainly to the presence of endogenous microbiological 
contaminants, bacteria and fungi, which are naturally present in the cervical region. The 
contamination of primary cultures is relevant due to this aspect. Notably, the higher the 
cervical preneoplastic grade, the higher the endogen microbial contamination and therefore 
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the risk of culture contamination. CIN2 and CIN3 tissues give the best primary culture 
results as  the  higher  the  preneoplastic  grade of  keratinocytes,  the higher  the  ability  to 
attach and proliferate clonally. On the contrary, keratinocytes from normal tissues attach 
slowly and differentiate rapidly and much fewer primary colonies can be obtained than 
with high grade CIN2-CIN3 tissues. Nevertheless, the successful rate of normal primary 
keratinocyte cultures is approximately 5-6 out of 10 and nearly 10 out of 10 of CIN2-CIN3 
primary keratinocyte cultures. This protocol is based on a cellular culture method, which 
was used in a recent publication of my lab (Bononi  et al., 2012) and employs the total 
number of cells, i.e. fibroblasts and keratinocytes, isolated from small tissue fragments of 
CIN or normal cervical tissue samples. The isolation of all the cells overcomes the issues 
arising from isolating pure populations of keratinocytes including low cell numbers and 
exogenous microbial  contamination,  and avoids  keratinocyte  loss  from starting  tissues. 
Although the presence of live fibroblasts is considered detrimental to keratinocyte cultures, 
due to overgrowth being caused (Freshney and Freshney 2002), this problem is avoided by 
seeding the all  cells  at  a very high dilution,  i.e.  in large culture surfaces.  In this  way, 
primary keratinocyte colonies can be obtained before fibroblasts colonize the cultures. On 
the other hand, high cell dilution allows keratinocytes to reach optimal density for clonal 
growth (Barrandon and Green, 1985, 1987). Furthermore, were formulated a new medium 
mixture which permits CIN and normal keratinocyte colonies to be expanded singly at a 
highly  proliferative  rate  for  different  passages  without  signs  of  differentiation. 
Immunofluorescence staining showed that CIN and normal keratinocyte primary colonies, 
as  well  as  expanded colonies,  expressed K14,  K17,  and K19 indicating  their  common 
origin  from basal  and  parabasal  layers  of  the  cervical  epithelia  (Smedts  et  al.,  1990, 
Martens et al., 2004; Akgűl et al., 2007). P63 stained strongly, with nuclear localization, in 
CIN3 keratinocytes  suggesting that those keratinocytes  present stemness characteristics. 
Indeed, p63 has previously been detected in stem cells from CIN and normal ectocervical 
epithelia (Quade  et al., 2001; Martens  et al., 2004).  Therefore, naturally HPV infected 
keratinocyte clones have the potential to provide valuable insights into the mechanisms 
induced by HPV during cervical cancerogenesis.  Since cultured cells represent a useful 
model for investigating the onset/progression of the carcinogenesis processes (Goldstein et  
al., 2011; Karst and Drapkin, 2012) and cellular and molecular studies on naturally HPV-
infected keratinocytes have been poorly reported, our protocol may provide opportunities 
for exploring mechanisms which occur during CIN transition, as well as gene expression 
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changes in progression toward cervical cancer in vitro, which to date is far from having 
been elucidated (Woodman et al., 2007; Galloway, 2009)
GENE EXPRESSION CHANGES AND CIN PROGRESSION
In  this  study,  gene  expression  changes  were  investigated,  for  the  first  time,  in 
naturally HPV16-infected CIN2 and CIN3 keratinocytes by microarray analysis. Since the 
majority of high-grade HPV16-CIN lesions are the result of 2-dimensional intra-mucosal 
extension of a single monoclonal cell population infected by the oncogenic HPV (Ueda et  
al.,  2003), two CIN keratinocyte  colonies,  representative of all  neoplastic keratinocytes 
comprising the CIN lesion, were chosen from each CIN tissue culture for the analysis of 
microarray. Moreover, in order to avoid the risk of a selection bias inherent in any long 
term in vitro growth, were collected CIN and normal keratinocyte colonies from primary 
cultures.  Were used DNA microarray technology in order to compare changes of gene 
expression, which characterize two key stages of progression of HPV16-cervical lesions in 
vivo. It was encouraging that the hierarchical clustering analysis of the data neatly grouped 
CIN keratinocytes together according to their status: CIN2 or CIN3. Moreover, the finding 
that our dataset contained many expected gene expression changes (such as those involving 
cell proliferation and differentiation) affirmed validity of the dataset. Therefore, the results 
obtained  in  CIN2  and  CIN3  keratinocytes  by  microarray  analysis  likely  parallel  the 
molecular  changes  that  underlie  progression  to  high-grade  HPV16  CIN.  Notably,  the 
number  of  genes  down-regulated  in  CIN3 keratinocytes  compared  with  the  number  in 
CIN2 keratinocytes  (n=211) was almost  double  that  in  normal  keratinocytes  compared 
with CIN2 keratinocytes (n=113). In contrast, 175 genes were increased significantly in 
CIN2  compared  with  normal  keratinocytes,  and  94  genes  were  increased  in  CIN3 
compared  with  CIN2 keratinocytes.  These  findings  suggest  that  the  majority  of  genes 
down-regulated and up-regulated during the progression of cervical neoplasia affect the 
transition  from CIN2 to CIN3 lesions  and from normal  to  CIN2 lesions,  respectively. 
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Twenty-three under-expressed and 14 over-expressed genes, which may play an important 
role in CIN progression, were selected. These genes are associated with HPV-mediated 
transformation,  including  the  down-regulation  of  antiviral  immune  response-inducible 
genes and up-regulation of proliferation-related genes. Indeed, INHBB, TLtlrR2, TIMP3, 
RARB,  IFIT2  and  EFNB2  were  consistently  under-expressed,  whereas  APOC1  and 
PHGDH were consistently overexpressed in CIN2 and CIN3 keratinocytes. Notably, most 
of the down-regulated genes, such as INHBB, TLR2, TIMP3 and RARB, are the target of 
promoter  methylation  in  various  tumours  (De  Oliveira  et  al.,  2011;  Gu  et  al.,  2008; 
Karpinski et al., 2011; Wang et al., 2005), including HPV-related cancers (Stephen et al., 
2010), high-grade CIN lesions (Terra et al., 2007), and HPV cervical cancers (Sun et al., 
2011), suggesting an important role of these genes in tumour development. Therefore, it is 
possible that the consistent decrease in mRNA expression in CIN2 and CIN3 keratinocytes  
accounts for increasing CpG-island methylations at the gene promoter level. In line with 
this, HPV16 can induce cellular gene promoter hypermethylation (Leonard  et al., 2012). 
These  findings  this  findings  leaded  me  to  explore  explore,  in  the  next  step  of  my 
investigation,  the  putative  link  between  gene  expression,  at  mRNA  levels,  and  gene 
promoter methylation status in high-grade CIN keratinocytes. A major feature of CIN2 and 
CIN3 keratinocytes is the consistent overexpression of genes that play a role in tumour 
invasiveness.  Indeed,  consistent  up-regulation  of  LPAR1,  a  pro-angiogenesis  gene 
(Hayashi  et al., 2012), and ARNTL2 (Mazzoccoli  et al., 2012), MSX1 (Chetcuti  et al., 
2011),  and  TAGLN (Rho  et  al.,  2009),  which  are  pro-invasive  genes,  was  present  in 
progression  from  CIN2  to  CIN3  keratinocytes.  These  findings  are  in  agreement  with 
results of a recent microarray study in which transition to CIN2 stage coincided with the 
activation  of  pro-angiogenesis  pathways,  whereas  the  transition  to  CIN3  and  then  to 
invasive cancer was characterized by a pro-invasive gene expression (Gius  et al., 2007). 
Therefore, these up-regulated genes detected in CIN2 and CIN3 keratinocytes likely are 
associated with cervical cancer and may be prognostic markers for CIN progression. An 
interesting  characteristic  of  CIN2  and  CIN3  keratinocytes  is  the  disruption  of  cell-
differentiation  programs.  Indeed,  a  series  of  differentiation-induced  genes,  such  as 
ALDH1A3 (Muzio  et al.,  2012),  IRX2 (Lewis  et al.,  1999),  IRF6 (Botti  et al.,  2011), 
SYNM (De Souza Martins et al., 2011), and ATP2A3 (Korosec et al., 2009), were down-
regulated in late-stage CIN keratinocytes. On the other hand, stemness-related genes, such 
as KLF2 (Gillich et al., 2012), were increased in the transition of CIN keratinocytes from 
CIN2 to CIN3. These data are in accordance with the oncogenic activities of HPV16 E6-
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E7  viral  oncoproteins  that  dysregulate  the  cell  cycle  through  differentiation  program 
disruption (Rosty  et  al.,  2005).  Finally,  two up-regulated  genes,  SCARA5 and SFRP2 
change in opposite directions in HPV-related tumors or other cancers (Huang et al., 2010). 
Further investigations are needed to clarify the role of these genes in CIN progression. I 
focused on one of the up-regulated genes, PHGDH, which encodes an enzyme that controls 
the  flux  from glycolysis  into  the  serine  biosynthesis  pathway,  although  a  novel  non-
metabolic role of PHGDH also has been reported. Various studies have found increasing 
PHGDH expression in human astrocytomas according to increasing tumour grade (Liu et  
al., 2013), and PHGDH recently was found overexpressed in cervical cancer (Locasale et  
al., 2011). These observations prompted me to investigate PHGDH expression in CINs and 
invasive cancer in order to explore its contribution to cervical carcinogenesis. Expression 
of PHGDH mRNA was continuously increased during conversion from normal to CIN2 
keratinocytes  and from CIN2 to CIN3 keratinocytes.  Consistently,  a  strong staining of 
PHGDH was observed in dysplastic cells from almost all CIN lesions and in tumour cells 
from all cervical cancer tissues, whereas expression was less and only in the proliferative 
compartment  of  the epithelium from normal  tissues,  a  finding which  suggests  that  the 
protein  expression  of  this  gene  is  enhanced  according  to  the  degree  of  malignant 
transformation. In conclusion, this microarray study revealed 37 down-expressed or over-
expressed genes which may contribute to progression of CIN. mRNA expression of one of 
the up-regulated genes, PHGDH, was significantly greater in CIN2 keratinocytes than in 
normal keratinocytes and in CIN3 keratinocytes than in CIN2 keratinocytes. In addition, 
protein expression of PHGDH increased from CIN1 to cancer according to the degree of 
malignant transformation. Thus, PHGDH likely plays an important role in the initiation 
and progression of cervical tumorigenesis and may be a prognostic marker for progression 
of CIN to invasive cancer.
GENES PROMOTER METHYLATION AND CIN 
PROGRESSION
Together  with  genetics  changes,  epigenetic  alteration,  such  as  improper  DNA 
promoter methylation, have an important role in cancer onset and progression. Indeed, the 
CpGs methylation status of some gene promoter regions is a significant prognostic variable 
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for various tumor types, including cervical SCC (Van Noesel et al., 2002; Shivapurkar et  
al.,  2004).  Particularly,  aberrant  promoter  methylation  play  a  important  role  in 
downregulation of  tumor suppressor genes in SCC.  This phenomenon could lead to cell 
transformation or cervical  SCC formation. As previously reported,  a certain number of 
tumor suppressor genes such as p16 (Nakashima et al., 1999), CCNA1 ( Yang et al., 2010) 
PTEN (Cheung et al., 2004), E-cadherin (Widschwendter et al., 2004) and APC (Virmani 
et al., 2001) present improper hypermethylation in cervical carcinogenesis. Furthermore, 
p16  hypermethylation  was  detected  progressively  higher  in  CIN pre-cancerous  lesions 
progression (Huang  et  al.,  2011).  Using DNA cloning and bisulfite  sequencing,  it  was 
investigated the  epigenetic  status  of  RARB  and  IRF6  promoter  region  in  neoplastic 
progression  of  CIN  pre-cancerous  lesions.  These  genes  have  been  suggested  to  be 
implicated as actual or potentitumour suppressor genes, and are aberrantly methylations of 
their promotereds were detected   in  variousdifferent cancers (Piperi  et al., 2010; Botti  et  
al., 2011).  The RARB gene encodes  for  retinoic  acid  receptor  beta,  a  member  of  the 
thyroid-steroid hormone receptor superfamily of nuclear transcriptional regulators, which 
binds the retinoic acid. Interaction of retinoic acid with RARB receptor induces cell growth 
and differentiation  as well  as embryonic  morphogenesis  (Soprano  et  al.,  2004).  RARB 
improper  methylation  was  detected  in  several  tumors,  like  breast  (Park  et  al.,  2012), 
prostate  (Serenaite  et  al.,  2015)  and ovarian  cancer  (Flanagan  et  al., 2013)  and 
oropharyngeal SCC (Van Kempen et al., 2014). Moreover, methylation defects in RARB 
promoter region were detected in CIN3 biopsies (Vasiljević  et al., 2014) and in primary 
human foreskin keratinocytes transfected with episomial form of HPV16 (Leonard et al., 
2013).
This study  shows,for  the  first  time, that  an  extensive  methylation  defects,  i.e. 
hypermethylation,  occur  at  the  RARB  tumor  suppressor  gene  promoter  in  naturally 
HPV16-infected  CIN2  and  CIN3  keratinocytes.  Similar data  were  obtained  data  were 
showed  in  HPV16-positive  exfoliated  cervical  CIN2 and CIN3 samples  (Chang  et  al., 
2011),  and  in  cervical  SCC  samples  (Narayan  et  al.,  2003).  In  the  present  study, 
hypermethylation of RARB gene promoter was significantly higher in CIN23 keratinocytes 
compared to CIN23 keratinocytes (p<0.05).  ThereforeFurthermore, these results indicate 
that  methylation  defects  at  the  RARB  locus  frequently  occur  in  CIN  keratinocytes, 
suggesting  that  increased methylation  of  the  gene  promoter  is  predictive  ofwith CIN2 
progression  towards  >CIN3 progression.  It  can  be  hypothesized  that  the  presence  of 
HPV16 could be involved in this improper promoter methylation, as previously reported 
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(Leonard  et  al.,  2012).  In my study, in  CIN2 and CIN3 keratinocytes  wereas found a 
progressive  down-regulation  of   RARB and  a  progressive  up-regulation  of  the proto-
oncogene  c-Jun transcript,  respectively (p<0.0001).  This  negative  correlation  between 
RARB and c-JUN was previously reported in Cervical Carcinoma HeLa Cells (De-Castro 
et al., 2004). It is conceivable that the progressive RARB hypermethylation may cause a 
consequent RARB mRNA down-regulation and this reduction of expression could enhance 
c-JUN expression (De-Castro et al., 2004). As previously mentioned, c-JUN expression is 
increased in in SV40 immortalized human epidermal keratinocytes, transfected with HPV-
16  E5  coding  sequence  (Chen  et  al., 1996).   Moreover,  it  is  know  that  HPV-16  E5 
suppresses the  expression of  tumor  suppressor  gene p21 by c-JUN activation  inducing 
human  keratinocytes  immortalization.  (Tsao  et  al.,  1996).  This  might  be  one  of  the 
mechanisms by which HPV-16 stimulates cell proliferation by c-Jun activation and p21 
inactivation. It is conceivable that the same molecular effect could occur in naturally HPV-
16-positive CIN keratinocytes used in my study. 
As  for  RARB,  this  study  shows  that  extensive  methylation  defects,  i.e. 
hypermethylation,  occur  also at  the IRF6 gene promoter  in  HPV16-positive  CIN2 and 
CIN3  keratinocytes.  This  gene  encodes  for  a  member  of  the  interferon  regulatory 
transcription  factor  (IRF)  family.  The  encoded  IRF6  protein  regulates  craniofacial 
development  and  epidermal  proliferation and  may  be  a  transcriptional  activator. 
ReFurthermore,  recently findings  suggest  have  suppose  that  IRF6  exhibits  tumor 
suppressor activity  IRF6  (Botti  et al., 2011). Despite the epigenetics data of the present 
study  show  extensive  DNA  hypermethylation  in  IRF6  gene  promoter  region  in  CIN 
keratinocytes compared to normal, this trend was not in progression between CIN2 and 
CIN3 keratinocytes. However, it  is appreciable a methylation increase, even though not 
statistically  significant  (p>0.05),  between these two groups.  These epigenetics  data  are 
consistent  with a work conducted by Botti  and colleagues,  where IRF6 gene promoter 
region was aberrantly methylated in primary SCCs cultures and SCC cell lines (Botti et al., 
2011). Furthermore, in the present study was observed a reduced IRF6 expression in the 
same cell cultures in association with hypermethylation of whose its IRF6 promoter region 
is hypermethylated.  Accordingly, in this work, In my work,  was detected a similar  IRF6 
expression  was  detected  to  be  reduced  trend  in  HPV16-positive  CIN2  and  CIN3 
keratinocytes were  IRF6  promoter  resulted  hypermethylated.  Specifically,  was 
evaluatedIndeed, it was observed  a progressively down-regulation of IRF6 transcript from 
normal  to  CIN2  as  well  as  from  CIN2  to  CIN3  (p<0.0001)  in  HPV16-positive 
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keratinocytes whit  progressive  CIN2 to  CIN3 IRF6 promoter  region hypermethylation. 
Therefore, it is conceivable that the hypermethylation of IRF6 promoter region may cause 
a  consequent  IRF6 transcript  reduction in  CIN keratinocytes.  It  is  known that  IRF6 is 
involved in squamous differentiation (Biggs et al., 2012). This biological effect is limited 
by  p63,  a  protein  present  in  squamous  epithelia  that promotes  renewal  of  basal 
keratinocytes (Okuyama et al., 2007). Furthermore, IRF6 is a p63 transcriptional target that 
limits  keratinocyte  proliferation  by  inducing  p63  proteasome-mediated  degradation 
(Moretti et al., 2010). In the present work an increased of p63 expression was detected an 
increased p63 expression  in HPV16-positive CIN2 and CIN3 keratinocytes compared to 
normal. This expression was confirmedevaluated also by immunofluorescence, where  p63 
resulted  highly expressed  in  CIN3  keratinocytes  with  nuclear  localization. 
MoreoverFurthermore, p63 transcript up-regulation resulted in progression from CIN2 to 
CIN3  and  in  progressive  negative  correlation  with  IRF6  expression (p<0.0001).  It  is 
conceivable  that  the  deregulation  of  this  molecular  loop,  altering  the  critical  balance 
between differentiation and proliferation during CIN progression, as previously reported in 
Neck Squamous  Cell  carcinoma (Nicolas  Stransky  et  al.,  2011),  ectodermal  dysplasias 
(Moretti  et al., 2010) and cleft palate (Thomason  et al., 2010). These findings led us to 
hypothesize that RARB and IRF6 gene promoter hypermethylation could be a potential 
prognostic epigenetic marker for HPV16-positive CIN progression. Such changes might 
therefore be used as markers of cervical neoplasia, either alone or in conjunction with other 
molecular prognostic markers. Furthermore, RARB, c-Jun, IRF6 and p63 deregulation may 
contribute to progression of CIN pre-cancerous lesions.
CONCLUSIONS
In conclusion,  in my study the molecular  mechanisms occurring in CIN lesions 
progression were investigated. In particular, it was investigated gene expression profiles 
and methylation status of gene promoters in a novel study model, i.e. primary colonies of 
CIN2  and  CIN3  keratinocytes  derived  from  HPV16-CIN2  and  CIN3  lesions.  Gene 
expression  analysis  revealed  37  down-expressed  or  over-expressed  genes  which  may 
contribute to CIN progression. One of these genes, the phosphoglycerate dehydrogenase, 
which  resulted  over-expressed  at  both  mRNA  and  protein  level  in  CIN2  and  CIN3 
65
keratinocytes and in CIN2, CIN3 and cancer tissues, respectively, is likely to be associated 
with  tumorigenesis  and  may  be  a  potential  prognostic  marker  for  CIN  progression. 
Aberrant promoter hypermethylation of RARB and IRF6 genes also may be a potential 
epigenetic prognostic marker for CIN progression.
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